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HIV/AIDS is a pandemic disease infecting millions of people worldwide.  The 
circumstance and life expectancy of HIV-infected patients have changed to a 
manageable condition with the aid of antiviral therapy.  Amongst all the HIV infections 
in South Africa, approximately 95% are of subtype C strain.  The core aim of this study 
was first, to investigate the flap dynamics of the C-SA HIV-1 PR in its free (apo 
enzyme) and bound forms by applying molecular dynamics (MD) simulations, and 
second to develop an effective computational model for the identification of potential 
novel PCU-based peptide HIV protease inhibitors, employing a structure-based virtual 
screening approach. 
HIV protease consists of two essential flap tips whose conformations and dynamics are 
crucially important for substrate entry to access the protease catalytic site for its 
mechanism.  There are few studies on MD simulations of C-SA HIV-1 PR for the 
investigation of enzyme flexibility.  MD simulations on the free enzyme as well as the 
docked PR complex of five previously reported PCU-based peptides were studied.  The 
dynamic behaviour of the free enzyme and the inhibitor-PR complex were compared to 
that of the ritonavir-enzyme complex.  An implicit solvation model was used and the 
MD simulation was performed over 10 ns.  The overall results of the free enzyme 
calculations showed that C-SA HIV-1 PR has greater flexibility in the flaps in 
comparison to subtype B.  For C-SA PR, the flap opening was observed at 3.5 ns and a 
fully-opened form of the protease at 8.6 ns.  During the 10 ns simulation, flap opening 
and closing of the C-SA protease was observed which confirms that suitable 
equilibration was reached and that the opening was not an artefact.  On the other hand, 
the subtype B PR was observed to open at 3.4 ns and remained opened for the entire 
simulation.   
MD simulations of the PR complexes with the five PCU-peptide inhibitors as well as 
ritonavir showed that all complexes attained a closed conformation.  In this study, four 
metrics have been used to estimate the flap flexibility: (1) the distance between the flap 
tips (Cα I50 - Cα I149), (2) the distance between the α-carbons of K55 and K154 
residues, (3) the distance between the flap tips and catalytic residues (Cα I50 - Cβ D25) 







angle formed from the α-carbons of residues G48-G49-I50 of monomer A and G147-
G148-I149 of monomer B were measured to monitor the flap-curling behaviour.  The 
first metric has often been used in most reported studies.  It was observed that the first 
metric takes flap-curling effect into account which can lead to erroneous interpretation 
of flap openings from the MD results.  The second metric is insensitive to flap-curling 
and movements observed correspond to real flap openings.  When the movement 
observed using the third metric, asymmetric behaviour of the flaps was observed due to 
the interaction of the inhibitor with the flaps and the catalytic site.  These interactions 
result in the shrinking of the active site thus, holding the inhibitor more tightly.  The 
four metrics do not clearly define the conformation of the flaps or the extent of flap 
opening. In this study, the second metric (Cα K55 - Cα K154) seemed to be more 
appropriate in estimating the extent of flap opening. 
 
This thesis also, involves the virtual screening of 640 PCU-based peptide compounds 
(R-Cage-R, with R = (R)- or (S)-amino acids) as potential HIV PR inhibitors.  This 
study was an attempt to gain insight into the possible structure-activity relationship 
(SAR) of these potential inhibitors against C-SA HIV-1 PR.  The pentacycloundecane 
(PCU) cage diol were either functionalised as HOOC-(CH2)n-Cage-(CH2)n-COOH or 
H2N-(CH2)n-Cage-(CH2)n-NH2 with n = 0, 1, 2 or 3.  Virtual attachment of a mixture of 
(R)- and (S)-amino acids to the cage result in four possible diastereomeric products: the 
(R,R)-, (R,S), (S,R)- and (S,S) forms of R-Cage-R, with R = (R)- or (S)-amino acids.  A 
total of 640 structures were docked into the active site of the C-SA PR and each family 
(acid or amide) with the sub-families (n = 0 – 3), were rank ordered according to the 
calculated binding energies.  The future plan in this regard is to start a new project to 
calculate the binding free energies from MD simulations of the 640 inhibitors after 
which the synthetic group will attempt the synthesis and HIV PR testing of the ten best 
compounds. 
Results obtained from this study provide deeper insight into the structural and 
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This chapter briefly explains the background of the Human Immunodeficiency Virus (HIV), a 
causative agent of Acquired Immunodeficiency Syndrome (AIDS)[1-4] including anti-HIV 
therapies employed in the past and today. 
 
1.1 Background 
AIDS is the most devastating disease outbreak to date.  It is caused by a previously unknown 
agent,[5] which was reported in the mid- to late 1970s[6].  Since it was demonstrated that HIV is 
the source of AIDS, serious research efforts on developing new and improved therapies targeting 
HIV were initiated.  Zidovudine (AZT) was synthesized in 1964 as a drug for cancer treatment but 
it was proven to be ineffective[6].  After the discovery that it inhibits HIV, it became the first drug 
to be approved by the United State Food and Drug Administration (FDA) in 1987 for HIV/AIDS 
treatment[7, 8].  The latest global figures from The Joint United Nations Programme on HIV/AIDS 
(UNAIDS) revealed that almost 2.7 million people were newly infected with HIV, 1.8 million 
AIDS-related deaths for both children and adults and 34 million people both adults and children 
were living with HIV in 2010[9]. 
Remarkable effort had been directed to the understanding of the HIV structure and life cycle since 
the spread of AIDS started to increase exponentially worldwide[5].  In nature, HIV exists in two 
forms, HIV-1 and HIV-2 which are closely related to the Simian Immunodeficiency Virus (SIV)[4].  
Three enzymes were found to be essential in the HIV-1 life cycle; thus, these enzymes were 
identified as potential drug targets.  These enzymes are reverse transcriptase (RT), integrase (IN) 
and protease (PR)[5].  This led to the development and improvement of antiviral drugs targeting 
different stages of the viral life cycle[5].  The mode of action of antiviral drugs is discussed in 
Section 1.3. 
The ineffectiveness of AZT monotherapy[7, 10] and the increased number of infected patients led 
to the introduction of combination therapy of the anti-HIV drugs targeting different mechanisms in 
the HIV-1 life cycle[11].  Since the mid-1990s a combination therapy which is known as Highly 
Active Antiretroviral Therapy (HAART) was introduced which has changed the condition and life 
expectancy in HIV/AIDS patients[11-13].  This treatment includes combinations of a protease 
inhibitor, a nucleoside reverse transcriptase inhibitor and a non-nucleoside reverse transcriptase 
inhibitor[13].  With the knowledge and understanding of the transmission and prevention of the 
virus, the use of anti-HIV drugs have changed the effect of the virus to a manageable condition and 






On the other hand, the long term use of anti-HIV drugs results in high prevalence side effects in 
patients[15-17].  Effects such as lipodystrophy[7], hyperlipidemia[13], hypertotoxicity, 
hyperglycemia, diarrhoea, insulin resistance[13], an increase in cardiovascular disease and birth 
defects have been reported in HIV/AIDS patients[13, 17, 18].  Hypertotoxicity, which is a common 
name for liver damage, and skin rash were observed in patients taking all FDA-approved anti-HIV 
drugs from nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse 
transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs)[19].  The use of PIs has been 
reported to cause hyperglycemia resulting in high levels of glucose in the blood stream.  Ritonavir 
was reported to cause hyperlipidemia, which is an increase in the amount of fat (such as cholesterol 
and triglycerides) in the blood, more than for any other PIs[19].  AZT dramatically accelerates 
patient somatic mitochondrial DNA mutations causing a much faster aging process, especially in 
terms of the brain. Patients also often develop heart disease, dementia, and other age-related 
illnesses[20]. 
Other than side effects, numerous drug resistant strains have developed[21].  Due to the observed 
side effects researchers are now aiming to discover anti-HIV drugs that will result in a simpler 
therapy with low toxicity, reduced resistance, long-lasting viral suppression, less side effects, better 
oral bioavailability and improved potency[22, 23]. 
 
1.2 The HIV-1 virus 
HIV is classified as a member of the Lentiviris subfamily of retroviruses[4, 8].  In 1983, HIV-1 was 
isolated by R.C. Gallo and L. Montagnier and few years later, HIV-2 was reported[1, 8, 24].  Both 
viruses cause AIDS but it was found that HIV-1 is the most widely spread virus worldwide.[8]  The 
structure of the HIV-1 virus is 100 nm in diameter[8] (Figure 1).  The viral particle is covered with 
a lipid-bilayer membrane traversed by surface glycoproteins (gp120), which are anchored via 
transmembrane proteins (gp41).  The matrix shell protein (p17) forms the inside liner surface 
beneath the lipid-bilayer membrane.  Capsid proteins (p24) form a cone-shaped arrangement that 
encloses the nucleocapsid proteins (p7 gag and p9 gag), reverse transcriptase, integrase and 
protease. HIV-1 carries three important genes namely, gag, pol and env[22].  These genes are 
articulated as large polyproteins which are processed into functional proteins by either the viral 
protease (gag and pol) or the host cellular enzymes (env).  The gag gene encodes a precursor 
polyprotein that is cleaved to capsid proteins, matrix shell proteins and nucleocapsid proteins.  The 
pol gene encodes for the three viral enzymes namely, reverse transcriptase, integrase and protease.  








Figure 1. Structure of an HIV-1 virion particle[8]. 
1.2.1 HIV-1 life cycle 
The HIV-1 virus infects T lymphocytes (T-cells) that carry a cluster of differentiation, namely the 
CD4 antigen, on their surface[4].  For the infection to be effective, it requires fusion with the viral 
and cellular membranes, see Figure 2[4].  When the virus enters the cell, its single-stranded 
ribonucleic acid (RNA) is reversed transcribed into double-stranded deoxyribonucleic acid (DNA) 
by reverse transcriptase in the host cytoplasm by means of the process called reverse transcription.  
This process is known to cause errors during the transcription process, resulting in frequent 
mutations for each generation of the virus produced.   
Nucleoside reverse transcriptase inhibitors, nucleotide reverse transcriptase inhibitors and non-
nucleoside reverse transcriptase inhibitors are designed to block the activity of the reverse 
transcriptase enzyme which are discussed in detail in Section 1.3.3[25]. 
The viral DNA is transported to the host nucleus, where the viral DNA is incorporated into the host 
DNA by the integrase enzyme forming a provirus.  This process is called integration and is blocked 
by integrase inhibitors, which are discussed in Section 1.3.4.  The virus replicates more frequently 
than the normal host DNA, without any detectable immune response and reaching concentrations of 
more than 100 million copies of the HIV-1 RNA/ml[8].   
The activation of the host cell results in the transcription of the viral DNA into messenger RNA 
(mRNA) in the nucleus.  The mRNA is transported to the host cytoplasm where it is translated into 
viral proteins.  The products of translation are host cellular enzyme (env) precursor polyproteins (in 
the endoplasmic reticulum) and transmembrane proteins, gag and gag-pol protein precursors (in the 
ribosomes).  All of these are then transported to the cell membrane.  These proteins assemble in the 
membrane to form a curvature that results in the formation of a bud.  HIV protease cleaves the new 






and the viral proteins gather at the surface into new virions where they bud from the host cell and 
are released to infect other host cells[4, 8, 26].  Therefore, protease inhibitors discussed in section 
1.3.5 effectively prevent this stage due to the absence of sufficient and the correct viral proteins. 
 
 
Figure 2. The replication cycle and targets for therapeutic intervention in the HIV life cycle[27]. 
 
Currently, there are several FDA-approved drugs commercially available for HIV/AIDS treatment.   
 
1.3 Antiretroviral therapy 
At present, a number of drugs are available on the market which is outlined in the following 
sections.  The United States Food and Drug Administration approved the drugs on market and the 
year of drug approval is shown in brackets.  These drugs are classified according to their therapeutic 
target in the HIV-1 replication cycle.  
 
1.3.1 Types of enzyme inhibitors 
Inhibitor types are classified based on the mechanism of action of inhibition.  Inhibitors can also be 






the second type is effective against any enzyme.  Non-specific inhibition can be caused by high 
temperature or extreme pH conditions and will lead to denaturing of the enzyme.  It is, therefore, 
irreversible in nature.    
Specific enzyme inhibition can be classified in reversible and irreversible inhibitors[28, 29]. 
The following are examples of reversible inhibitors.   
 
• Competitive inhibitors 
A competitive inhibitor is specific and has characteristics that diligently resemble the chemical and 
molecular geometry of the substrate thus, competing for the same enzyme active site as the 
substrate.  The inhibitor binds precisely where the substrate binds thus, the bound inhibitor prevents 
the substrate from binding to the active site.  This inhibition is reversible if sufficient substrate 
concentration is available to displace the competitive inhibitor from the active site[30, 31]. 
 
• Non-competitive inhibitors  
A non-competitive inhibitor is also specific and binds to the free enzyme or enzyme-substrate but 
generally not at the active site.  This leads to a change of the shape of the enzyme especially the 
active site so that the substrate can no longer effectively bind to the enzyme.  Non-competitive 
inhibition is usually reversible and binds non-covalently to the enzyme[28, 30-32]. 
 
• Uncompetitive inhibitors 
An uncompetitive inhibitor is structurally different from the substrate and it binds only to the 
enzyme-substrate complex.  The binding of the inhibitor to the enzyme–substrate complex results in 
the loss of activity of the enzyme[30, 32]. 
 
• Mixed inhibitors 
In this kind of inhibition, the inhibitor does not only compete with the substrate for binding to the 
enzyme but also bind to an enzyme molecule that subsequently binds a substrate or binds to an 
enzyme-substrate complex to affect catalytic turnover[32].  The binding of the inhibitor to the 
enzyme influences the binding of the substrate to the enzyme since it alters the protein’s 
conformation[30]. 
 
Irreversible enzyme inhibition 
Irreversible inhibitors form covalent interactions with the enzyme hence, forming a stable complex 






labels (active site-directed irreversible inhibitors) and the mechanism-based irreversible enzyme 
inactivators[28]. 
 
• Affinity labels and active site-directed irreversible inhibitors 
The affinity labels are usually reactive chemical entities since they contain electrophilic groups.  
They target any nucleophilic group in the protein, especially those in the active site.  These entities 
resemble the substrate structure and can bind to the enzyme thus, covalently modifying the enzyme.  
Normally, they tend to be unselective in their mode of action.  Therefore, inherently toxic and they 
have little therapeutic value[28, 29]. 
 
• Mechanism-based irreversible enzyme inhibitors 
These kinds of inhibitors are also called suicide substrates.  They are normally unreactive but 
become activated during catalytic processing.  In their intermediate reactive state, they can 
irreversibly alkylate a nucleophilic amino acid group in the enzyme.  This action causes the enzyme 
to denature (suicide)[28, 29]. 
 
1.3.2 Entry inhibitors 
Entry inhibitors are competitive in character and prevent the entry of the virus into the host cell.  In 
this section, entry inhibitors are explained according to their mode of action and examples are also 
shown.  
 
1.3.2.1 Attachment or Binding inhibitors 
These classes of compounds disrupt the initial binding or attachment of the HIV-1 gp120 surface 
protein to the CD4 T-cell surface receptor by one of the several possible mechanisms.  Figure 3 



























Figure 3. Structures of attachment or binding HIV inhibitors[8, 33]. 
 
On the other hand, there are inhibitors designed to fuse with the host cell membrane.  This kind of 
inhibitor is described in detail in the next section.   
 
1.3.2.2 Fusion inhibitors 
The first fusion inhibitor was approved by the FDA in 2003.  It is a linear, 36-amino acid synthetic 
peptide which corresponds to residues 127-162 of the viral glycoprotein (gp41) named 
enfuvirtide[7, 34] (see Figure 4).  This drug inhibits the conformational change of the gp41 which is 
required for fusion of the viral and host cell membrane.  Therefore, the viral RNA is prevented from 
entering the host cell.  Unfortunately, synthesis of the drug is difficult and expensive and it can only 






















































































































Figure 4. The structure of a fusion inhibitor[6]. 
 
1.3.2.3 Co-receptor Antagonists inhibitors 
There are two co-receptors namely, CCR5 and CXCR4 found on the surface of the T-cell.  Co-
receptor antagonists were the first antiretroviral drugs, which do not target the HIV virus directly, 
but they block the HIV attachment to the cell by preventing the virus from interacting with the co-
receptors.  Lead drugs targeting the CCR5 co-receptor include monoclonal antibody, Pro140 which 
blocks HIV-1 infection by occupying the gp120 binding site on CCR5[8].  Maraviroc was the first 












Maraviroc (2003)  
Figure 5. The structure of CCR5 antagonist maraviroc[35, 36]. 
 
HIV-1 reverse transcriptase enzyme is one of the important targets for antiviral therapy.  The next 
section will describe the mechanism of action and associated FDA-approved drugs. 
 
1.3.3 Reverse transcriptase inhibitors 
These inhibitors interfere with the reverse transcription process of the viral RNA into DNA.  In this 
section, reverse transcriptase inhibitors are explained according to their structural properties and 
mode of action and examples are also shown. 
 
1.3.3.1 Nucleoside reverse transcriptase inhibitors 
As mentioned earlier, AZT, a nucleoside reverse transcriptase inhibitor (NRTI) was the first drug 
approved in 1987 for treatment of HIV[7].  Unlike the natural deoxynucleotides substrates, NRTIs 
lack the 3'-hydroxyl group on the deoxyribose moiety[8].  These drugs are covalently bonded to the 
DNA.  Incorporation of NRTI during DNA transcription prevents further covalent addition of 
nucleosides because the 5'-3' phosphodiester bond cannot be formed, therefore, transcription is 
terminated[8].  Currently, there are seven approved NRTIs on the market.  Examples of some 


























Zidovudine (1987) Didanosine (1991) Lamivudine (1995)  
Figure 6. The structures of the nucleoside reverse transcriptase inhibitors approved by the FDA[7, 
36]. 
 
The next section will outline other kinds of reverse transcriptase inhibitors, which exhibit less 
toxicity than nucleoside reverse transcriptase inhibitors.   
 
1.3.3.2 Nucleotide reverse transcriptase inhibitors 
The mode of action for nucleotide reverse transcriptase inhibitors is the same as with nucleoside 
reverse transcriptase inhibitors and they also form a covalent bond with DNA.  The human body 
normally converts the nucleoside into a nucleotide through a phosphorylation process.  The 
incorporation of a nucleotide skips the first phosphorylation process which might lead to 
toxicity[8].  Viread (Tenofovir), an example of a nucleotide analogue reverse transcriptase inhibitor, 
















Viread (2001)  
Figure 7. Structure of a nucleotide reverse transcriptase inhibitor[7, 36]. 
 
The next section describes another kind of reverse transcriptase inhibitor which is commercially 







1.3.3.3 Non-nucleoside reverse transcriptase inhibitors 
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) which were first described in 1990 
interact specifically with the non-substrate binding site (allosteric site) on RT of HIV-1 is, 
therefore, it blocks its replication due to conformational changes at the active site of the enzyme[8].  


































Delaviridine (1997) Efavirenz (1998)
Etravirine (2008) Rilpivirine (2011)  
Figure 8. Structures of the non-nucleoside reverse transcription inhibitors[7, 35]. 
 
HIV-1 integrase enzyme is an important drug target and the next section will describe the mode of 
action of integrase inhibitors. 
 
1.3.4 Integrase inhibitors 
The development and advancement of the research on HIV-1 integrase inhibitors has lagged behind 
for almost a decade because of insufficient knowledge of the integrase structure.  Integrase 
inhibitors block the integrase enzyme, which is essential for the HIV-1 replication cycle by 
blocking the integration of the viral DNA into the host genome.  Raltegravir was the first integrase 




















Figure 9. Structure of integrase inhibitor approved by FDA[8, 37-39]. 
 
The HIV-1 protease also plays an important role in the HIV-1 life cycle since it is responsible for 
viral maturation.  The next section describes the mode of action of the PR inhibitors. 
 
1.3.5 Protease inhibitors 
The clinical practice of HIV protease inhibitors (PIs) (see Figure 10) was brought into use in 
1995[23].  In 1995, saquinavir was the first PR drug approved for clinical practice[23].  The 
advantages of HIV-1 protease inhibitors include prolonged viral control, better viral suppression, 
reduction of the indication of HIV infection and reduction of death rates[23].  HIV PR treatment is, 
therefore, very beneficial to patients infected with HIV.  A sound understanding of the virus and its 
life cycle have attracted researchers’ interest in the discovery of new PIs[8].  The mechanism of 
action for the drug is to inhibit the catalytic activity of the protease then preventing new virions 
from maturing.  This renders the virions into a non-infectious state[8].  One limitation with HIV PIs 































































































































A comparative study of the binding affinities was recently reported for nine FDA-approved drugs 
(ritonavir, amprenavir, saquinavir, indinavir, nelfinavir, lopinavir, darunavir, tipranavir and 
atazanavir) against HIV-1 subtype B PR and C-SA HIV-1 PR.  It was found that from the nine 
investigated drugs, most inhibitors exhibited slightly weaker binding affinities for C-SA HIV-1 PR 
than subtype B PR[40].  Therefore, development of new drugs with better binding affinities is 
needed for the C-SA HIV-1 PR.  
In this study, pentacycloundecane-based compounds as HIV-1 PR inhibitors will be looked at in 
more detail. 
 
Other developments in terms of HIV drug research 
A recent review article outlined the use of nanopharmaceuticals as potential anti-HIV therapies[26].  
Nanopharmaceuticals such as nanocrystals, nanocapsules, nanoparticles, solid lipid nanoparticles, 
nanocarriers, micelles, liposomes and dendrimers have been studied.  Some of these 
nanopharmaceuticals exhibit antiviral activity by targeting different aspects of the HIV-1 life cycle.  
However there are limitations to the delivery of drugs with nanoparticles due to biological 
challenges, toxicity, cost and difficulties for scaling up[26].  Nanopharmaceuticals is a developing 
field of research. 
 
1.4 HIV-1 protease enzyme 
The fully functional form of the HIV-1 protease that is needed for the virus to survive is the 
homodimeric form (22 kDa) and not the monomeric (11 kDa), inactive form.  The protease cleaves 
newly synthesized polyproteins to produce mature HIV virion[4]. 
 
1.4.1 The structure of HIV-1 protease 
The HIV-1 protease is classified as a C2 symmetric active homodymeric aspartyl protease which is 
essential for the HIV-1 life-cycle[14, 23].  The enzyme consists of 99 amino acids per monomer 
and the position of each monomer forms an axis of symmetry[14].  The secondary structure of each 
monomer consists of one α-helix and two antiparallel β sheets.  There are three domains in the 
enzyme shown in Figure 11 which is referred to as the active site cavity (the core domain), terminal 
domain (dimerization domain) and the flap domain[41].  From generation to generation, it has been 
observed that the nucleotide sequence of HIV-1 protease changes[4].  However, the tripeptide 
sequence found in each monomer i.e. Asp25-Thr26-Gly27 is conserved[14].  The enzyme is 






found in each subunit.  Therefore, the two Asp25 residues act as the catalytic residues during 
hydrolysis[4, 8, 14].  
 
Figure 11. Structure of HIV-1 protease. 
 
The HIV-1 PR has three domains which are described in the next section. 
 
• Active site cavity (core domain) 
The tripeptide Asp25-Thr26-Gly27 is found at the interface of the core domain formed by the two 
monomers.  This domain plays an important role in the stabilization of the dimer and the catalytic 
site[4, 5, 14]. 
• Terminal domain (dimerization domain) 
The terminal domain consists of antiparallel β sheets which are formed by the four termini in the 
dimer of residues 1-4 and 95-99[34].  This domain is important in dimer formation and stabilization 
of an active protease.  
• The flap domain 
Flaps are two hairpin turn structures which are made up of amino acid residues 43-58 found in both 
monomers[14, 42-44].  These flexible regions cover the active site and have a great effect on 
ligand/inhibitor binding interactions.  It has been revealed from the crystal structure of the HIV-1 
protease that the flaps exhibit great mobility ranging from closed form, semi-open form and wide-
open form[42, 43, 45].  In the closed form state the active site is occupied by the ligand while the 
wide-open form state allows the active site to be accessed by the substrate and the inhibitor[42, 43, 






Although the HIV-1 PR has been crystallized as a single monomer (accession 1HHP pdb code),[46] 
it functions in the dimeric form.  The dimer is observed in complexes of the HIV-PR with 
inhibitors.  The dimer is formed due to intermolecular forces that contribute to its stability and the 
next section will describe these forces. 
 
1.4.2 The stability of HIV-1 protease 
The aliphatic residues found in the PR dimer stabilize each monomer in a hydrophobic core[34, 47].  
In addition, the stabilization of the HIV protease dimer is achieved by factors such as non-covalent 
interactions, hydrophobic packing of side chains and interaction involving the catalytic 
residues[47].  A hydrogen bonding network present in the catalytic site is shown in Figure 12[5, 
14]. 
 
Figure 12. The catalytic residues of the tripeptide of Asp25-Thr26-Gly27 forming a hydrogen bond 
network (green lines) [47]. 
 
1.4.3 Substrate binding 
The active site pocket is made up with several well-defined subsites where side chains of the 
substrate can be accommodated upon binding.  The subsites for each monomer are named S1 to Sn 
and S1' to Sn' (the prime symbol, 1 to n denotes the direction from the N-terminal to the C-terminal 
direction[5]) while the amino acid residues of the substrate are named as P1 to Pn and P1' to Pn', 
when counting from scissile bond (see Figure 13) that is cleaved during hydrolysis[48].  As a result 
of the C2 symmetric character of the protease subsites S1 and S1' are the same and this holds for the 


































scissile bond  
Figure 13. The standard nomenclature representing P1 _ _ _ Pn, P1'_ _ _ _ Pn'_ for amino acid 
residues of peptide substrates. The corresponding binding sites on the protease are referred to as S1_ 
_ _ Sn, S1'_ _ _ _ Sn'_ subsites[4]. 
 
1.4.4 HIV-1 protease catalytic mechanism 
Proteases are degradative enzymes, which catalyze the hydrolysis of peptide bonds with high 
sequence selectivity and catalytic proficiency[4, 48].  There are two broad classes of protease 
enzymes, i.e., exopeptidases and endopeptidases.  These proteases are classified according to their 
catalytic mechanism[4].  The exopeptidases hydrolyze the peptide bond nearer to the amino or 
carboxyl termini of the substrate, while endopeptidases hydrolyze the peptide bonds far away from 
the termini of the substrate[48].  These two classes of enzymes are further classified into four 
groups, i.e., serine proteases, aspartic proteases, cysteine proteases and metalloproteases, based on 
the functional groups present at the catalytic site[48].  HIV-1 protease is an example of aspartic 
endopeptidase proteases since it has Asp25-Thr26-Gly27 residues at the catalytic site.  HIV-1 
protease cleaves the gag and gag-pol protein by an acid-base mechanism (see Figure 14)[13, 14, 
51].  The aspartic protease catalyzes the hydrolysis of the peptide bond by activation of a water 
molecules which then attacks the amide bond carbonyl of the substrate’s scissile bond.  This results 
in an oxy-anion tetrahedral intermediate (see Figure 14)[4, 14].  Activation of one of the water 
molecule results due to the combined action of the two aspartyl β-carboxyl groups at the active 
site[4, 25].  The protonation of the amide nitrogen is followed by a breakdown of the tetrahedral 








Figure 14. Schematic representation of the cleavage mechanism of HIV-1 protease[4, 25]. 
 
Scope of this study 
Polycyclic cage compounds have been reviewed intensively[53-57] and have shown antiviral, 
pharmacokinetic and pharmacodynamic properties which are explained in more detail in Section 
1.5.  
In this study, we employed molecular dynamics (MD) simulation studies using Amber software, to 
investigate the subtype C South African (C-SA) HIV-1 protease motion and also, Autodock 4.0 was 
used for docking the PCU-based compounds in the active site of the C-SA HIV-1 protease.  A 
background for computational studies is presented in Chapter 2. 
1.5 Polycyclic cage compounds 
Polycyclic cage molecules have been extensively studied as potential chemical scaffolds for the 
development of new drugs due to the broad range antiviral properties amantadine had shown[58, 
59].  Incorporation of the cage into bioactive molecules has revealed pharmacokinetic and 




































































to the hydrophobicity of the hydrocarbon cage.  In addition, the steric effect and rigidity of the cage 
results in the metabolic degradation process being retarded thus, prolonging the activity and 
reducing the frequency of drug administration to the patient.  The rigidity of the cage also induces 
receptor site specificity in antibacterial activity, anabolic action and analgesic activity[25, 58].  The 
introduction of advantageous properties by cage molecules has inspired our group to develop new 
potent polycyclic cage peptides for potential treatment of HIV-1. 
Peptides show potent pharmacological properties and are specifically recognized by protease 
enzymes[52].  In our group, protease inhibitors with the pentacycloundecane (PCU) frame work 
with either peptides or peptoids as side chains have been synthesized, and tested for activity[60-70].  
The first study involved the synthesis and biological testing of PCU-lactam peptides against C-SA 
HIV-1 PR and the inhibitor reported an IC50 of 78 nM[60, 61].  The second study involved a PCU-
ether peptide with the inhibitor exhibiting an IC50 = 600 nM[66].  In the third study, PCU-lactam 
peptoids were reported with similar activities (500 nM).  The fourth study involved the synthesis of 
PCU-diol peptoids and the inhibitor with IC50 = 7500 nM was reported[64].  The fifth study 
involved the synthesis PCU-diol peptides and the inhibitor with IC50 = 500 nM was reported[63]. 
In this study, PCU-based compounds were investigated by employing computational methods such 
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Introduction to computational chemistry 
Theoretical methods used in this thesis 
This chapter outlines the computational and theoretical chemistry tools used in this study.  A recent 
review from our group describes the combination of drug design, molecular modelling and 
spectroscopic techniques[1].  This review also presents a thorough overview of available 
computational techniques for this purpose.   
There are two basic methods of computational chemistry; namely, quantum mechanics and 
molecular dynamics.  The first is based on electronic structure methods, solving the Schrödinger 
equation and the second on the classical laws of physics.  The first is much more costly in terms 
computational resources and time and is therefore, only practical for smaller systems (up to 100s of 
atoms), while the second can handle much larger biochemical systems of tens of thousands of 
atoms[2].  Hybrid method such QM/MM/MD will also be discussed in Section 2.10. 
 
2.1 Quantum Mechanics 
In everyday life, basic principles of classical mechanics is applied but fails when applied to the 
transfer of very small energies and to objects with very small masses; therefore, quantum mechanics 
originated[3-5].  In quantum mechanics, all properties of a system are expressed in terms of a wave 
function that is obtained by solving the Schrödinger equation[3]. 
 
2.2 Schrödinger equation 
In 1926 Erwin Schrödinger proposed an equation referred to as the time-independent Schrödinger 







+   𝑽 𝒙 𝝍 = 𝑬𝝍   Eq. 1 
Where V(x) is associated with the potential energy of the particle at point x; m is the  particle mass; 
ψ is the wave function of the quantum system; E is the sum of potential and kinetic energies and ħ 
is the Planck’s constant, 6.626 x 10-34Js.  
The Schrödinger time-independent wave equation can also be defined by combining the classical 
differential equation which describes the profile of a simple harmonic standing wave and De' 



















+ 𝑽 𝒓 .𝝍 𝒓 = 𝑬.𝝍(𝒓)   Eq. 2 
Where ψ (r) is related with any set of i particles with masses mj and V(r) is the potential field in 
which the particles are moving and r refers to the set of component vectors of each particle as a 
function of x, y and z coordinates.  Eq.2 can also be written in its abbreviated form: 
𝑯𝝍 = 𝑬𝝍   Eq.3 
In the Schrödinger equation, H is the Hamiltonian operator which is the sum of the kinetic energy 
(T) and the potential energy (V) operators[7-9]. 
𝑯 = 𝑻+ 𝑽   Eq. 4 
 
Where H is defined as follows:  















   Eq. 5 
The Born-Oppenheimer approximation (see Section 2.3) was then introduced, when using Eq. 5 
could not solve molecular systems. 
 
2.3 Born-Oppenheimer approximation 
The Born-Oppenheimer approximation shows how the electronic motion can be approximately 
separated from the nuclear motion[6, 7].  It tries to separate the electronic and nuclear degrees of 
freedom even though they are coupled by the electron-nuclear potential energy.  In most cases, the 
Hamiltonian operator can be simplified by using the Born-Oppenheimer approximation, since the 
mass of the nucleus is much greater than that of an electron and the nuclei move very slowly with 
respect to the electron while the electrons react quickly to changes in nuclear positions[7-9].  Thus, 
the electron distribution within a molecular system can be approximately described if the nuclei 
have fixed positions while their kinetic contributions in the kinetic operator are not taken into 
consideration[8, 9]. 












𝒊    Eq. 6 
Whereby the Schrödinger equation for electrons in the fixed nuclei is written as:  
𝑯𝒆𝒍𝒆𝒄𝝍𝒆𝒍𝒆𝒄 𝒓,𝑹 =   𝑬𝒆𝒇𝒇(𝑹)𝝍𝒆𝒍𝒆𝒄(𝒓,𝑹)   Eq. 7 
Where Eeff(R) is the effective electronic energy which depends on the relative nuclear coordinates 






is the electronic coordinates and R is the nuclear coordinates.  Solving this equation for other fixed 
positions of interest will produce a Potential Energy Surface (PES)[6, 9].  Specific points of interest 
on the PES are minima (low energy conformations) and maxima (saddle points or transition states).   
 
2.4 Potential Energy Surface 
A PES is a mathematical function that requires the systematic calculation of energies of a molecule 
or system as a function of its geometrical arrangements[2, 3].  Quantum mechanical computational 
techniques take into account electronic correlation which arises from instantaneous interactions 
between electrons as they move closer and further from each other in a molecular orbital[3].  A 
model surface of the energy as a function of the molecular geometry and interesting features are 
outlined in Figure 15.  The most interesting points on the PES’s are the stationary points where the 
gradients with respect to all internal coordinates are zero.  Stationary point includes local or global 
minima which corresponds to the low energy equilibrium molecular structures and saddle points[2].  
Saddle points are the lowest energy barriers on the path connecting minima that relates to the 
concept of a transition state[2]. 
 
 
Figure 15. An example of two-dimensional potential energy surface[10].  
 
2.5 Molecular Mechanics 
Molecular mechanics (MM) uses the law of classical physics to explain and interpret the behaviour 






over quantum mechanics is that it relies on force-fields with embedded empirical parameters and 
can be used for molecules as large as enzymes because it does not calculate electronic properties[5, 
7].  Conformational analysis or energy minimization is perhaps the single most important 
application of molecular mechanics[12].  The main components of a force field comprise of a set of 
equations explaining how the potential energy of the molecule varies with locations of its 
component atoms, and a series of atom types defined by the characteristics of an atom of the 
element within a specific chemical context[11]. 
There are drawbacks that accompany molecular mechanics models[5, 7].  First, they are limited to 
the description of equilibrium geometries and equilibrium conformations.  Second, it does not 
calculate electronic properties; therefore, it gives limited information about the bonding.  It cannot 
be used for the calculation of bond formation/breaking.  Thus, chemical reactivity and selectivity 
cannot be predicted.  Third, the force fields used mostly nowadays are parameterized using 
experimental data or alternative data from ab initio techniques.  Last, the accuracy of molecular 
mechanics depends not only on the choice of parameters but also on experimental studies and the 
parameterization, which is normally based on small number of model systems[5, 7, 12].  It is 
important to note that a specific force field is designed for a specific family of molecules (proteins 
etc.) and it may not work for a completely different system. 
MM consider a molecule to be a collection of masses interacting with each other through harmonic 
forces.  Thus, the MM total energy of a molecule is defined by the sum of contribution resulting 
from bonded interactions such as bond length, bond angles, torsions and non-bonded interactions 
such as Van der Waals and electrostatic[6, 8, 11, 12]. 
𝑬𝒕𝒐𝒕 = 𝑬𝒔𝒕𝒓 + 𝑬𝒃𝒆𝒏𝒅 + 𝑬𝒕𝒐𝒓𝒔 + 𝑬𝒗𝒅𝒘 + 𝑬𝒆𝒍𝒆𝒄….   Eq. 8 
Where Etot is the total energy, Estr is the bond-stretching energy, Ebend is the angle-bending energy, 
Etors is the torsional energy, Evdw is the Van der Waals energy and Eelec is the electrostatic energy.  
The combination of such sets of energies constitutes molecular mechanics force fields[7-9, 13, 14]. 
 
2.5.1 Force fields 
Numerous molecular mechanics force fields have been developed and used today.  Force fields such 
as AMBER, CHARMM, OPLS and GROMOS are the most popular and the most used set of 
parameters applied for simulation for biomolecules[12, 15].  All force fields have different 
parameters due to differences of the parameterization process, the atom types and the reference 
data.  Thus, these force fields are referred to as set of variables that must be adjusted to give results 






In this study, AMBER[16] force fields were used.  The General AMBER Force Field (GAFF) is 
used to parameterize the ligands while the standard AMBER force field was used for the protease.  
2.6 Homology models 
Homology modelling is also known as comparative modelling of proteins such as enzymes[17].  
The lack of high resolution, three-dimensional (3D) structural information of proteins from X-ray 
crystallography, multidimensional NMR spectroscopy and other experimental methods resulted into 
the development of homology modelling.  This method refers to the construction of a target protein 
from its amino acid sequence and 3D structural information of a related homologous protein used as 
a template[1, 17].  There are several steps normally required for constructing a model[1]. 
• Search and select:  
A known 3D structure with about 25% or better similarity in the primary structure than the target 
protein with unknown 3D is searched and selected 
• Align: 
The sequences of the known and unknown proteins are aligned.  During alignment the structurally 
preserved and variable regions will be identified.  
• Model:  
The target protein coordinates for the structurally preserved regions are modelled from those of the 
protein template with known 3D structure.  The conformation of the loops and side chains are also 
constructed without the template and this might results in inaccuracy. 
• Evaluate: 
The constructed model is then evaluated. 
In this study, homology modelling was not used to model C-SA HIV-1 PR from subtype B HIV-1 
PR.  This was not required since the required changes were manually introduced.  The construction 
of C-SA HIV-1 PR is described in detail in Chapter 3.  The crystal structure of C-SA HIV-1 was 
recently solved[18]  and gave an excellent correlation with the model we have created.  
Molecular docking method is used for the prediction of the bound geometry and interactions of 
small organic molecules (ligands, substrates) with their biological targets (receptors such as 
enzymes)[19].  Normally, it is recommended to employ virtual screening before experimental work 
to save time and costs.  The next section will describe molecular docking. 
 
2.7 Molecular Docking 
Computational methods are becoming more important in studying the structure and function of 






Molecular docking is mostly used in structure-based rational drug design to identify correct 
conformations of small molecule ligands and also to estimate the strength of the protein-ligand 
interaction.  Molecules such as substrates, inhibitors or other drug candidates are identified in the 
active site of the macromolecule.  Macromolecules are proteins such as a receptor, enzyme or 
nucleic acid with a known 3-dimensional structure[23, 24].  Molecular docking forms a link 
between the structural component and the synthetic compound in rational drug design[25].  The 
binding energy between the ligand and the macromolecule is analyzed by using molecular 
mechanics[20].  Molecular mechanics is explained in detail in Section 2.5 
The binding energy is calculated as follows: 
𝑬𝒃𝒊𝒏𝒅𝒊𝒏𝒈 = 𝑬𝒕𝒂𝒓𝒈𝒆𝒕 + 𝑬𝒍𝒊𝒈𝒂𝒏𝒅 − 𝑬𝒕𝒂𝒓𝒈𝒆𝒕!𝒍𝒊𝒈𝒂𝒏𝒅   Eq. 9 
There are more than 60 different docking programs for both commercial and academic work [23] 
such as Dock[26], AutoDock[27], FlexX[28], Surflex[29], Gold[30], Glide[31], Cdocker[32], 
LigandFit[33], MCDock[34] and others.  The proposed docking programs can be categorized into 
four broad categories namely, stochastic Monte Carlo, fragment-based, evolutionary-based and the 
shape complementary methods[23].  Docking programs do not use a systematic search to explore all 
degrees of freedom fully because of the computational costs[23]. 
There are two types of docking namely, rigid and flexible docking.  In rigid docking both 
macromolecule and ligand are kept rigid while in flexible docking the flexibility is allowed for the 
macromolecule (or selected part thereof) or the ligand or both[35].  In this study, we have employed 
AutoDock 4.0[36] for docking a flexible ligand in the active site of the rigid HIV-1 protease to 
estimate the strength of the protein-ligand interaction.  AutoDock is an evolutionary method that 
uses the genetic algorithm to perform conformational searches and it uses the Lamarckian version 
of genetic algorithm.  The Lamarckian genetic algorithm [27] can handle ligands with larger 
number of degrees of freedom[37].  In the Lamarckian genetic algorithm new conformations are 
adapted from changes in the conformation of molecules after in situ optimization and the strength of 
the interaction between the ligand and the protein would be determined[23]. 
Mukherjee et al., employed three different docking experiments, i.e., rigid docking, fixed anchored 
docking and flexible docking[19].  From the three experiments, it was reported that maximum 
errors were from scoring function at 1.5-2.0 Å.  Therefore, it was concluded that general failures in 
docking are significantly due to scoring functions than sampling[19].  Until now, there is no scoring 
method developed to consistently identify the correct binding mode for any given protein-ligand 
complex[5].  Scoring failures in docking measures the inability of the energy function to allocate 
the best score to a correctly sampled conformation out of the ensemble generated.  A more accurate 






bonds affects the results.  The success rate for ligands containing rotatable bonds of 7-0, 8-15 and 
15 plus, can be ranked as 7-0> 8-15> 15 plus[19].  In this study, PCU-diol peptides with ≥ 12 
rotatable bonds were investigated.  Thus, these compounds have a high probability of rendering 
poor results.  As the ligand flexibility increases its success rate during docking decreases[19].  The 
use of a single approach such as a hybrid method implemented by combining different existing 
docking techniques might maximizes advantages and minimizes disadvantages[38]. 
 
2.8 The Austin Model 1 (AM1) semi-empirical approximation 
In semi-empirical methods, many of the integrals are estimated by using quantum physics, or 
experimentally-derived empirical parameters.  It also uses a series of rules to set certain integrals 
equal to zero[3, 4, 7, 8].  In this study, AM1 BCC charges[39] are used during ligand preparation.  
The AM1 method is based on the Neglect of Diatomic Differential Overlap (NDDO)[2, 12, 40].  If 
two electrons are defined by two basic functions then the two-electron integral is:  
∅𝒂 𝟏 ∅𝒃 𝟏
𝟏
𝒓𝟏𝟐
∅𝒄 𝟐 ∅𝒅(𝟐)𝒅𝝉𝟏𝒅𝝉𝟐   Eq. 10 
Where basic functions a and b are used to define electron 1 and basic functions c and d are used to 
define electron 2[7].  Examples are shown in Figure 16, Figure 17 and Figure 18. 
 
Figure 16. The AM1 evaluation for two-center two electron interaction integrals where electron 







Figure 17. The AM1 evaluation for one-center two electron interaction integrals[12]. 
 
 
Figure 18. A case where AM1 method is not applicable because it omits two-electron repulsions 
over three and four centers[12]. 
 
After assigning atomic charges and other system settings with AMBER, a MD simulation is 
performed.  The following section will explain how the MD method works. 
 
2.9 Molecular Dynamics 
A molecular dynamics (MD) simulation is defined as a form of computer simulation programme 
which aims to reproduce the time-dependent behaviour[9, 41, 42] of a molecule due to atom 
vibrations, movements and collisions that results from the interactions between the atoms and 
molecules for a period of time by approximations of known physical attributes for a system of 
particles at a given temperature[4, 11].  In a molecular dynamic simulations the molecule is set in 
motion by heating to a specific temperature to overcome potential energy barriers and to achieve 
more conformations at high temperature[3, 14].  Molecular dynamics calculations are based on 
molecular mechanics principles[14, 43, 44].  The conformations are generated by integrating 
Newton’s laws of motion[8, 9, 45].  The result is a trajectory that specifies how the positions and 






force on each particle (Fi) first as a function of time, which is equal to the negative gradient of the 
potential energy: 
𝑭𝒊 =   −
𝝏𝑼
𝝏𝒓𝒊
   Eq. 11 
Where U is the potential energy function and r is the position of the particle.  From Newton’s Law 
of motion, acceleration (a) of a particle is determined by dividing the force acting on it by the mass 
of the particle[4, 8]. 
𝒂𝒊 =   −
𝑭𝒊
𝒎𝒊
   Eq. 12 
The change in velocities of the particle is equal to the integral of acceleration over time and the 
change in position is equal to the integral of velocity over time: 
𝒅𝒗 = 𝒂𝒅𝒕,   Eq. 13 
𝒅𝒓 = 𝒗𝒅𝒕   Eq. 14 
Lastly the kinetic energy can be described in terms of both the velocities and momenta of the 
particles[4, 8]. 
𝑲 𝒗 = 𝟏
𝟐
𝒎𝒊𝒗𝒊𝟐𝑵𝒊!𝟏 ,  Eq. 15 





𝒊!𝟏    Eq. 16 
Therefore, the total energy of the system is called Hamiltonian (H) which is the sum of the kinetic 
and potential energies:  
𝑯 𝒒,𝒑 = 𝑲 𝒑 + 𝑼(𝒒)   Eq. 17 
Where q is the set of Cartesian coordinates, p is the momenta of the particles and U(q) refers to the 





𝒒𝒊(𝒕)   Eq. 18 
Where qi(t) refers to the atomic positions at a particular time, t. Based on the initial atom 
coordinates of the system, new positions and velocities of the atoms at time t and the atoms will 
move to these new positions.  Thus, new conformations are generated[8, 11].  The temperature of 
the system is directly proportional to the average kinetic energy. 
In order to obtain more accurate and precise results hybrid methods are employed.  The next section 







2.10 Hybrid method (QM/MM/MD) 
In this methodology, the system is divided into two parts.  The small reactive part of the chemical 
system is defined by quantum mechanics (QM) whereas the remaining large non-reactive part is 
defined by molecular mechanics (MM) and treated with a force-field calculation (see Figure 19)[5].  
A MD simulation is then applied to the entire system.  The advantage of this methodology is that it 




Figure 19. An example of a hybrid QM/MM/MD model. 
 
Factors that affect quantitative analysis when using this methodology[5]: 
• Requires good ab initio description for the QM part 
• Requires extensive sampling while accessing free binding energy numbers which is 
computationally expensive. 
• Require calibration of the interaction between the QM part and the MM part which is difficult for 
biochemical systems such as enzymes. 
With the results from MD simulation, the binding free energy of complexes can be calculated.  The 
next section will describe how the binding free energy is calculated. 
 
2.11 Binding free energy 
The binding free energy of a molecular system plays an important role in predicting the ability to 
associate and react[44, 47].  In this study, the binding free energy calculations are performed for the 
ligands binding to C-SA HIV-1 PR enzyme by using the Molecular mechanics Generalized Born 
Surface Area (MM-GBSA) method implemented in Amber 11[16].   








The binding free energy ΔGb is calculated as follows: 
𝜟𝑮𝒃 =   𝜟𝑮𝑴𝑴 + 𝜟𝑮𝒔𝒐𝒍 − 𝑻𝜟𝑺   Eq. 19 
Where ΔGMM is the molecular mechanics (MM) representing the interaction energy between the 
protein and the ligand, ΔGsol is the solvation free energy and TΔS is for the entropy contribution to 
the binding[48, 49]. 
The ΔGMM term is calculated from the MM interaction energies as follows: 
𝜟𝑮𝑴𝑴 =   𝜟𝑮𝒆𝒍𝒆𝒄𝒊𝒏𝒕 +   𝜟𝑮𝒗𝒅𝒘𝒊𝒏𝒕   Eq. 20 
Here, ΔGelecint and ΔGvdwint are the electrostatic and Van der Waals interaction energies between the 
protein and the ligand, respectively[48, 49]. 
On the other hand the ΔGsol term can be separated into two parts as follows: 
𝜟𝑮𝒔𝒐𝒍 =   𝜟𝑮𝒆𝒍𝒆𝒄𝒔𝒐𝒍 +   𝜟𝑮𝒏𝒐𝒏𝒑𝒐𝒍𝒂𝒓𝒔𝒐𝒍   Eq. 21 
In this case, ΔGelec sol and ΔG nonpolar sol are the electrostatic and nonpolar contribution of the 
solvation free energy and nonpolar contributions to the solvation free energy is calculated as a 
linear function of the solvent accessible surface area (SA)[48, 49]. 
𝜟𝒏𝒐𝒏𝒑𝒐𝒍𝒂𝒓𝒔𝒐𝒍 = 𝛄𝐒𝐀+ 𝐛   Eq. 22 
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Comprehensive molecular dynamics flap movement analysis 
of the HIV PR free enzyme and complex with the natural 
substrate and various inhibitors 
 
3.1 Abstract 
HIV protease (PR) flap flexibility is crucial for substrate entry to access the catalytic 
site for effective hydrolysis of the natural substrate.  In this study, we have proposed 
and tested several metrics for obtaining optimum analysis of the flap dynamics.  
Molecular dynamic simulations have been employed to reach four goals.  First, 
comparison of the flap flexibility between subtype B and C-SA HIV-1 PR was carried 
out to provide greater insight into the impact of polymorphisms on the enzyme 
flexibility.  Second, different approaches to estimate the extent of flap dynamics of PR 
have been adapted to accurately measure flap flexibility.  Third, the impact of different 
classes of PCU-based inhibitors on the flap dynamics of C-SA HIV PR was studied and 
compared to both the natural substrate as well as ritonavir.  Last, to investigate to what 
extent the natural flap dynamics should reflect critical qualitative information about the 
nature of the interaction between the inhibitor and the HIV PR.  Results were compared 
against the measured IC50 for the synthesized PCU-based inhibitors.  It was observed 
that an implicit solvent MD model explores the complete conformational profile in a 
much shorter time (10 ns) in comparison to explicit solvent systems.  The metric 
parameter for measuring the distance between the Cα K55 – Cα K154 gave the best 
measure for monitoring flap movement since it is not affected by flap-curling and flap 
asymmetry.  The overall results showed that C-SA PR has higher flexibility in the flaps 
compared to subtype B strain both for the free enzyme and inhibitor/enzyme complexes.  
When looking at the MD results and the flap movement measurements for complexes it 
is clear that a quantitative relationship between the reported activities (IC50) and the 







AIDS still is a major health threat caused by a previously unknown agent that was 
reported in the mid-to-late 1970s[1-20].  Since the discovery that HIV is the causative 
agent of AIDS, extensive research on the development of new and improved therapies, 
targeting HIV, were conducted[1, 9, 21-23].  Human Immunodeficiency Virus type 1 
protease (HIV-1 PR) was found to be one of the therapeutic targets[1, 9].  HIV-1 PR is 
classified as a C2 symmetric homodimeric aspartyl protease with 99 amino acids from 
each monomer (see Figure 20)[9, 24].  The enzyme is essential for the virus’s life cycle 
since it cleaves the gag and pol polyproteins into building blocks required for the 
formation of mature virions during its replication[9, 24].  The structure of the protease 
consists of three domains, which are referred to as the active site cavity, terminal 
domain (dimerization domain) and the flap domain[9].  The active site consists of the 
two tripeptide Asp25-Thr26-Gly27 units found at the interface of the core domain 
formed by the two monomers and is essential for dimer stabilization and the catalytic 
mechanism[9].  Ligand entry to access the active site is regulated by the two glycine-
rich β-hairpin turn structures called flaps[9, 25-30].  The flap domain consists of amino 
acid residues from 43-58 in each subunit[25-27, 30, 31]. 
 






Various computational and experimental studies such as MD simulation[12, 23, 25-30, 
32-40], NMR[30, 31, 41] and X-ray[30], have investigated the flap-opening and closing 
mechanism of the HIV-1 protease subtype B for the ligand-bound PR and unbound 
enzyme[12, 25-30, 42].  It was reported that upon binding of the ligand to the HIV-1 
PR, the flaps are pulled inward to tighten around the active site[26, 27, 30].  In the case 
of the free enzyme, however, the flaps are relatively distal from the active site but still 
substantially cover the catalytic triad and remain in contact with each other[26, 27, 30].  
In most reported studies, two distinctive flap conformations are commonly observed; 
these are the closed form for the ligand-bound PR and the semi-opened form for the free 
enzyme[26, 27, 30, 43].  Several computational studies have intended to provide more 
insight into HIV-1 PR flap opening dynamics using different simulation protocols.  
Hornak et al. found, in unrestrained implicit solvation MD simulations in Amber with 
ff99 force field for the protein, that the open form of the free enzyme was in dynamic 
equilibrium with the closed and semi-open forms[26, 27, 30].  Toth and Borics 
employed MD simulations using Imagiro molecular mechanics program and OPLS-AA 
force field with GB/SA implicit solvent model to explore the mechanism of flap motion 
for the free and bound enzyme[28, 29].  They found that, during the simulation, the 
substrate induced the closing of the flaps into the closed conformation in an 
asymmetrical way through a hydrophobic intermediate state cluster.  The same authors 
proposed that a network of weakly polar interactions between the flaps seems to be 
responsible for the stabilization of certain flap conformations over the others.  Scott and 
Schiffer reported another unique feature of flap motion using MD simulations found in 
GROMOS96 package and the 43A1 force field with the SPC/E water model[25].  The 
results showed that the flaps curl in and burry the hydrophobic tips, Ile50 and Ile149, 
against the hydrophobic inside wall of the active site groove, to allow enough space for 
the inhibitor to access the active site[25]. 
Different metrics have been proposed to describe the various flap conformational states 
of HIV-1 PR.  The most commonly used one is based on the distance between the α-
carbons of Ile50 and Ile149 residues[26-30, 44, 45].  This distance was observed to be 
5.8 Å, 4.3 Å and 30 Å for the closed, semi-open and fully-opened conformations, 
respectively[26, 27, 30].  Another parameter based on the distance between the α-






report by Galiano et al.[46] and Torbeev et al.[47].  The MD simulations were 
performed using Amber 9 with a ff99SB force field.  According to this metric, the 
distances of 28 Å, 34 Å and 43 Å represent closed, semi-opened and fully-opened 
forms, respectively[12].  Recently, estimation of the Ile50 - Asp25 or the Ile149 – 
Asp124 distance was believed to be more realistic since it monitors the flap tip-tip 
(Ile50 - Ile149) distance, because the flap tip-tip distance can be affected by both flap 
tip curling and flap asymmetry[48, 49].   
We have previously reported the first account of the flap flexibility of the unbound C-
SA HIV PR[50], expressed in the laboratory of our co-workers.  MD simulations in 
explicit solvation with ff03 force field were employed and the distance between the α- 
carbons of the flap tips (Ile50 – Ile149) were measured.  These results demonstrated that 
the flaps of C-SA PR exhibited more flexibility than subtype B PR as the former is 
missing the E35-R57 salt bridge; which likely contributes to flap stability[50].  The first 
African HIV-1 subtype C PR (3U71.pdb) was solved at a 2.7 Å resolution[50].  It was 
found that subtype B and C-SA PR do not show significant difference in the overall 
tertiary folding.  Crucial hinge-located variations have been identified at residue 36, 
(one for each part of the dimer) which are apparently closely related to E35-R57 salt 
bridge formation as seen in the C-SA PR and may be implicated in drug resistance via 
effects on flap dynamics. 
 
In the current study, we aim to further explore the conformational changes of the flaps 
upon binding with different classes of pentacycloundecane (PCU) based cage peptide 
and peptoid inhibitors that were synthesised and tested for activity in our laboratory[14-
17, 51-54].  To that end, we performed MD simulations for four independent models: 
(1) the free enzyme, (2) PCU-peptide/peptoid PR complexes, (3) ritonavir PR complex 
and (4) natural peptide inhibitor PR complex.  The structures of the inhibitors and 
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Figure 21. Structures of the five PCU-based compounds[14, 17, 51, 52, 54], 







We performed simulations (Amber software with the ff99SB force field) in both explicit 
and implicit solvents.  Results were compared to previously published reports on 
subtype B HIV PR, where applicable.  Moreover, we used several different metrics to 
determine the best descriptors to obtain optimal information about flap motion.  
Comparison of the MD results for the four models will enable us to answer the question 
to what extent analysis of flap dynamics can be used as a measure of effectiveness of 
different HIV PR inhibitors.  Furthermore, this study can potentially guide us towards 
the design of more active HIV PR inhibitors.   
 
3.3 Material and methods 
 
3.3.1 Computational Simulation 
The following sections present an outline of the ligands and receptors used for 
molecular modelling.  It also provides details about the software and the parameters that 
were employed. 
 
3.3.1.1 Preparation of PCU-derived peptide/peptoid inhibitors and 
Ritonavir 
Figure 21 presents the structures of the five PCU-based compounds[14, 17, 51, 52, 54], 
ritonavir[55] and natural substrate[56] model that were investigated in this study; the 
PCU–based compounds are peptides and peptoids.  The PCU based HIV-1 PR 
inhibitors were constructed and optimized with the molecular mechanics optimization 
force field implemented in Hyperchem 6.0 software[57].  The ionization states of the 
aliphatic amine and carboxylic acid groups of the PCU-based inhibitors were reported 
to have no significant effect on the docking results when they are either in the neutral or 
ionized states[16]. 
Docking of the five neutral compounds against C-SA protease was performed.  From 
the Protein Data Bank, 1HXW and 1A8K accession codes (subtype B HIV-1 PR) were 






and natural substrate (1A8K) by using USCF Chimera software[58].  The minimized 
PCU inhibitors were then subjected to docking studies to obtain a favourable inhibitor 
conformation within the PR active site.  
3.3.1.2 C-SA HIV-1 PR enzyme model system 
Since the X-ray structure of the South African HIV-1 protease subtype C[50] (C-SA 
PR) was not available at the time we started this work, a model for C-SA PR was 
constructed from the reported X-ray data of subtype B HIV-PR (PDB accession code 
1HXW) [55].  C-SA HIV PR differs from subtype B at eight positions; T12S, I15V, 
L19I, M36I, R41K, H69K, L89M and I93L (see Figure 20)[59].  Details for the 
construction and the validity of the modelled C-SA HIV have been demonstrated 
before[16, 17, 51, 54, 59-61].  The X-ray structure of C-SA PR has in the meantime 
been reported[50] and subsequent comparison between our model turned out to be 
favourable.  The crystal structure of C-SA HIV PR was aligned with the modelled 
structure of C-SA PR by using VMD software[62] (see Figure 22) and the calculated 
RMSD was 1.03 Å.  
 
Figure 22. The structure showing the aligment of the 3U71.pbd and the modelled C-SA 






3.3.1.3 Docking of the five PCU-based inhibitors, natural substrate 
and ritonavir into the active site of the C-SA HIV-1 PR model and 
subtype B 
Before docking, all the PCU derived inhibitors were aligned and superimposed to 
ensure that all starting structures had the same 3D orientation with respect to the active 
site since this was found to improve the accuracy of the procedure.  The docking 
approach adopted in this study has been fully described before[16, 54].  Ritonavir was 
not docked as the X-ray structure of the type B complex (1HXW) was used for 
subsequent MD studies.  The X-ray structure of an analogue of the CA-p2 site 
(1A8K)[56] was used for MD analysis (see Figure 21) for the substrate structure (Arg-
Val-Leu-r-Phe-Glu-Ala-Nle-NH2)).  Note that this is the same sequence (Ala-Arg-Val-
Nle-p-nitro-Phe-Glu-Ala-Nle-NH2) that was synthesised in our lab[15] and used for in 
vitro testing of the IC50 values of these inhibitors.  The only small change introduced is 
the nitro group at the para position on the phenylalanine, in order to monitor the 
catalytic activity of the protease.  
Docking studies were performed using the AutoDock software[63, 64].  During the 
procedure, Geisteger partial charges were assigned and AutoDock atom types were 
defined using the AutoDock Tool graphical user interface supplied by MGL Tools[65].  
The docked conformations were generated using the Lamarckian Genetic Algorithm, 
which is the best method compared to simulated annealing method docking available in 
AutoDock[63].  The initial population was set at 150, the number of Genetic Algorithm 
cycles set at 10 and the maximum number of generated structures (conformations) at 27 
000.  The dimension of the grid parameter files defined in AutoDock Tools was X= 52 
Å, Y= 40 Å and Z= 40 Å and that of the center grid box was and X=16.572 Å, Y= 
24.503 Å and Z= 2.179 Å.  All other parameters were left with the default values.  The 
docked conformations of each inhibitor were ranked into clusters based on the binding 
energy.  The program was set to automatically choose only the top ranked 
conformations, which were visually analysed and selected for MD simulation.  
Selection was based on the binding energy and whether a chemically sensible position 
of the inhibitor was present in the active site.  The chosen docked complex structures 






3.3.1.4 Preparations of the PCU-based compounds, natural substrate, 
ritonavir and receptor for MD simulation 
All complexes selected for the MD simulation were extracted from the docking log file 
(dlg) generated from the docking results for each investigated PCU-based 
peptide/peptoid inhibitors.  Hydrogen atoms were added to the ligands, natural substrate 
and ritonavir with the Avogadro software[66] while keeping the amine and carboxylic 
groups in a neutral state.  All hydrogen atoms were deleted from the receptor (subtype B 
and subtype C PR) since LEaP module in Amber 10[39] adds them.  Visual inspection 
of each complex was performed to ensure that the correct structures were generated.  
The prepared systems were then used for MD simulation in Amber 10[39].  In the 
current study deprotonated states for the Asp25/Asp124 of the PR were considered 
since it was reported that docking of the C-SA complexes where either Asp25/Asp124 
were protonated, gave similar docking behaviour to the unprotonated Asp25/Asp124 
residues[15].  Also, MD simulations of the monoprotonated and deprotonated 
Asp25/Asp124 of the PR gave similar binding free energies[67]. 
 
3.3.1.5 Molecular dynamics simulations 
A) Explicit solvation 
The MD simulation was performed using the AMBER 10 software[39] with the 
AMBER force field, ff99SB.  All-atom force field parameters of inhibitors were 
obtained using the ANTECHAMBER module and the Generalized Amber Force Field 
(GAFF)[68] and AM1 BCC charges[68] were used to obtain force fields parameters for 
the ligands.  The LEaP module in AMBER added hydrogen atoms of the receptor.  The 
protein was placed at the center of cubic box with TIP3PBOX 8.0 Å and approximately 
8482 water molecules were added.  Six chloride ions were randomly added to neutralize 
the system to balance the +6 charge of the HIV-PR.  The particle-mesh Ewald 
method[69] was used to handle long-range electrostatic interactions.  The system was 
partially minimized, first to avoid insufficient pre-equilibration by 2500 cycles of 
steepest descent minimization; this was followed by 1000 cycles of conjugated gradient 
minimization under harmonic restraints with force constant 10 kcal/(mol·Å2) to all 






were allowed to move while the protein and the ligand were held fixed.  The system was 
then fully minimized with no restraint for 200 steps.  Canonical ensemble (NVT)-MD 
was then carried out for 30 ps, during which the system was gradually heated to 300 K 
for 30 ps.  The Shake algorithm[70] was applied to constrain the bonds that contained 
hydrogen atoms.  The time step of the simulation was 2.0 fs.  Finally, the 50 ns 
isothermal isobaric ensemble (NPT)-MD simulation was applied to the simulations 
without any restraints.  The temperature was regulated at 300 K using the Langevin 
thermostat[71, 72] and the pressure was maintained at 1.0 atm using isotropic positional 
scaling.  Trajectories were analysed every 1 ps using the PTRAJ module. 
 
B) Implicit solvation 
 Aqueous solvation was also modelled implicitly by using the Generalized Born 
approach[73].  The MD simulation was performed with the AMBER force field, 
ff99SB.  All-atom force field parameters of inhibitors were obtained using the 
ANTECHAMBER module and the Generalized Amber Force Field (GAFF)[68] and 
AM1 BCC charges[68] were used to obtain force fields parameters for the ligands.  The 
LEaP module in AMBER added hydrogen atoms of the receptor.  Six chloride ions 
were randomly added to neutralize the system to balance the +6 charge of the HIV-PR.  
The system was partially minimized, first to avoid insufficient pre-equilibration by 2500 
cycles of steepest descent minimization; this was followed by 1000 cycles of conjugated 
gradient minimization under harmonic restraints with force constant 10 kcal/(mol·Å2) to 
all solute atoms.  A non-bonded cut-off was not applied.  The system was then fully 
minimized with no restraint for 200 steps.  Canonical ensemble (NVT)-MD was then 
carried out for 30 ps, during which the system was gradually heated to 300 K for 30 ps.  
The Shake algorithm[70] was applied to constrain the bonds that contained hydrogen 
atoms.  The time step of the simulation was 2.0 fs.  Finally, the 10 ns isothermal 
isobaric ensemble (NPT)-MD simulation was applied to the simulations without any 
restraints.  The temperature was regulated at 300 K using the Langevin thermostat[71, 
72] and the pressure was maintained at 1.0 atm using isotropic positional scaling.  






3.4 Metric parameters for estimation of flap movement 
analysis 
In this study four different metric parameters (three distances and one dihedral angle) 
were used to measure the extent of flap opening; these are as follows: (1) the distance 
between the α-carbon atoms of I50 and I149 residues[26-30, 44], (2) the distance 
between the α carbon atoms of K55 and K154 residues[12], (3) the distance between the 
catalytic site and flap tip for each PR monomer[48, 49].  For monomer A, the distance 
was measured between the α-carbon atom of I50 and β-carbon (α-carbon) atom of D25 
while the distance between the α-carbon atom of I149 and β-carbon (α-carbon) of D124 
for monomer B was measured.  (4) The angle formed from the α-carbons of residues 
G48-G49-I50 of monomer A and G147-G148-I149 of monomer B were measured to 
monitor the flap-curling behaviour.  These metric parameters have been employed for 
the subtype B PR[12, 26-30, 44, 48, 49].  In this study these metric parameters were 
employed for both subtype B and C-SA PR and ligands complexed with C-SA PR for 
evaluating the extent of flap movement.  It should be noted that metric (1) is known to 
generate misleading results with type B PR[12].  It was decided to nevertheless employ 
it for C-SA PR in order to determine if the same phenomenon is also observed. 
The root-mean-square deviation (RMSD) and root-mean-square fluctuation (RMSF) of 
the unbound PR and complexes were also measured.  All snapshots were created with 
the Chimera software[58].  The distance, RMSF, RMSD measurements over the 
trajectories were generated using the Ptraj module of Amber 10[39].  Comparisons of 
the reported IC50 with MD studies for the complexes are discussed after defining all 
metrics. 
 
3.5 Results and discussion 
Achieving a molecular view of the enzyme movements in solution is difficult by any 
experimental methods.  To provide such insight we performed MD simulations with 
explicit solvation starting from a closed form of the unbound C-SA HIV-1 PR.  In order 
to measure the extent of flap movement, a metric parameter for measuring the distance 






between Ile149 and Ile50 is shown in Figure 23 A; however, when employing this 
method, it was observed that there was no significant change in the enzyme movement 
in the MD simulations up to 52 ns.  The change at about 9 ns is a small one (~3 Å), 
representing a slightly curled form of the flaps when compared with that observed for 
the implicit solvent simulations (for the implicit solvent model typical changes are up to 
~28 Å.  See Figure 23 B. 
There were no major changes observed in the explicit solvation calculations and this 
method was computationally expensive and time consuming.  Thus, it was decided to 
rather use an implicit solvation model for the remainder of this study.    
 
Figure 23. The evolution of the distance between the α carbon of residues I50 and I149 
during the MD simulation in A (explicit solvation) and B (implicit solvation) of free C-
SA PR. 
 
A 10 ns MD simulation in implicit solvation was employed to investigate the C-SA 
HIV-1 PR flap motion.  For comparison between subtype B and C-SA proteases the 
root-mean-square deviation (RMSD) for the α-carbon flap residues (43-58 residues) 







In the HIV PR structure, residues 43-58 and 142-157 represent the flap region.  The 
RMSD of flap A showed an average of 1.3682 Å and 1.3526 Å for subtype B PR and C-
SA, respectively while flap B exhibited 1.2186 Å and 1.2906 Å for subtype B and C-SA 
PR, respectively.  The RMSD plots represent deviations of the obtained conformation at 
a given time from the initial conformation; however, the similarity of the values makes 
it difficult to draw conclusions from the RMSD.   
 
Figure 24. The RMSD of the Cα of the flap atoms of (A) residue 43-58 of monomer A 
and (B) residues 142-157 of monomer B (implicit water solvent). 
 
The root mean square fluctuations (RMSF) of the proteases were plotted and shown in 







Figure 25. The RMSF for the subtype B and C-SA HIV-1 PR.  Residues 43-58 and 142-
157 represent the flap region for monomer A and B, respectively (implicit water 
solvent). 
There is a significant difference between monomer A (Figure 25 A) flap residues for 
subtype B and C-SA PR.  In contrast, monomer B (Figure 25 B) flap residues showed a 
smaller difference; this large change in the flap movements implies that C-SA PR 
exhibits greater flexibility than subtype B PR; a similar result was also reported by 
Naicker et al.[50].   
In order to evaluate the effectiveness of the proposed metric parameters, visual 
inspection of the MD trajectory was performed to determine representative 
conformations of the respective flap movements during the course of the MD 







Figure 26. Snapshots of the unbound subtype B HIV-1 PR (implicit water solvent). 
 
An initial closed form of the subtype B PR was observed which opened at 3.4 ns and 
remained in this form for the entire simulation.  This shows that the subtype B flaps are 
essentially fixed in the opened form during the whole MD simulation. 
Figure 27 shows snapshot views of the C-SA PR which demonstrates that the enzyme 
exhibits different structural conformations.  The initial conformation was closed.  At 1.2 
ns a curling form was observed which was also previously reported, by Scott et al.[25].  
Curling precedes flap opening.  In our study, one flap remained in the semi-opened 
form while the other flap was curled towards the P1 loop (residues Pro79, Thr80 and 
Pro81).  A semi-opened form of the protease was observed after the curling 
conformation (at 2.0 ns), which resulted in a opened conformation at 3.5 ns.  The flaps 
returned to the semi-opened conformation at 4.3 ns.  At 5.2 ns a fully-opened 
conformation was observed and the flap separation (the Ile149-Ile50 distance) reached a 






These results indicate that C-SA PR is much more flexible than subtype B PR.  
 
	  
Figure 27. Snapshots of the unbound C-SA HIV-1 PR (implicit water solvent at 300K).	  
 
Evaluating the distance between the flap tips (between the α-carbon of I50 
and I149) as suitable flap dynamics metric.  
Unbound C-SA HIV PR 
Karthink et al. reported that measurements of the distance involving the α-carbon atoms 
of residues Ile50 and Ile149 to monitor flap movements are misleading since it shows a 
contradictory trend in the distance of the semi-open form (4.3 Å), closed-form (5.8 Å) 
and opened form (>10 Å) of the unbound subtype B PR[12].  In this study it was found 
that the distances for the closed, semi-opened and opened forms of unbound C-SA were 






different trend from the one for subtype B reported by Hornak et al. [26].  An example 
of misleading results from this metric is a false positive result at the distances around 10 
Å, which suggest that the flaps were open.  On closer inspection the enzyme structure 
represents flap-curling or a semi-opened form.   
This metric parameter was also used to probe the flap movement of the 
inhibitor/enzyme complexes.  
Inhibitor bound C-SA PR 
In the current study ritonavir was used as a reference inhibitor since it is an approved 
drug for HIV/AIDS treatment targeting the protease enzyme.  The flap movements of 
five PCU-based inhibitors, PCU-diol peptide, PCU-diol peptoid, PCU-ether peptide and 
PCU-lactam peptide and PCU-lactam peptoid (shown in Figure 21), complexed C-SA 
PR were compared to the ritonavir complex and the unbound enzyme (see Figure 28).  
The Ile50 and Ile149 distances for the ritonavir/C-SA PR complex and the unbound C-
SA PR are shown in all plots for direct comparison.  All the plots in this study are 
presented in this fashion.  Ritonavir was found to adopt a closed conformation (see 
Figure 28) from 0 to 6 ns with distances of less than 10Å; however, after 6 ns the 
conformation constantly changed from the closed to the semi-opened form (about 10 
Å).  This semi-opened conformation was due to the interaction of the substrate with the 







Figure 28. The evolution of the distance between the α-carbon atoms of residues Ile50 
and Ile149 (implicit water solvent, 300K).  The peptide/peptoid structures are presented 






For the PCU based compounds (Figure 28 A-E) it was observed that there is a 
significant difference between the Ile50 and Ile149 distances for the complexes and the 
unbound C-SA PR; for all the investigated cage compounds there is a reduction of the 
distances compared with the unbound C-SA HIV-1 PR.  It is clear that the 
ritonavir/enzyme complex is tighter than the PCU-diol peptide complex (Figure 28 A) 
while PCU-diol peptoid (Figure 28 B) shows similar distances to the ritonavir/enzyme 
complex at 0-2 ns and at 6-10 ns.  Analysis of the flap movement shows that PCU-ether 
peptide and PCU-lactam peptide compounds (Figure 28 C and D) behave similar to 
ritonavir, although it is clear that ritonavir forms a tighter complex.  The other PCU-
lactam peptoid (Figure 28 E) behaves similarly at the first 4 ns but slightly differently 
(show larger distances) for the rest of the simulation.  These results suggest that in all 
cases that ritonavir (IC50 = 22–13 nM) forms tighter complexes than the PCU-based 
complexes.  The PCU inhibitors that induce tighter complexes according to this metric 
are the PCU-ether peptide (IC50 = 600 nM), PCU-diol peptoid (IC50 = 7500 nM) and 
PCU-lactam peptide (IC50 = 78 nM) (Figure 28 B, C and D). 
Natural substrate-bound subtype B and C-SA PR 
From the measured distances in Figure 29 A, it was found that the ritonavir and the 
natural substrate complexed with subtype B gave relatively similar distances (about 10 
Å) for the entire simulation.  In some cases the natural substrate complex exhibited 
slightly lower distances (above 6 ns).   
Figure 29 B, shows a comparison of the Ile50 and Ile149 distances for ritonavir and the 
natural substrate complexed to the C-SA PR.  It is clear that both complexes behave 








Figure 29. The evolution of the distance between the α-carbon atoms of residues I50 
and I149 in the subtype B PR (A) and C-SA PR (B)  (implicit water solvent, 300K). 
 
Also the complexes for subtype C-SA show a tighter system than for subtype B.  For C-
SA, ritonavir and the natural substrate both gave distances around 6 Å during the first 
4.5 ns, which represent a closed form.  However, after 4.5 ns, the ritonavir complex 
interchanged its conformation between the closed and semi-opened form and this was 
due to interactions with the C-SA PR flaps more than the active site.  The substrate is 
held and fixed in one conformation while the ritonavir complex shows interaction (close 
contacts) with the flaps.  
 
Evaluating the distance between the flaps (Cα K55 and Cα K154) as a 
suitable flap dynamics metric.  
Unbound C-SA PR 
Karthik and his colleagues introduced a new parameter for monitoring the flap opening 
by measuring the distance of the α-carbon atoms of residue K55 and K154.  When using 
this parameter for subtype B, it was observed that the distance of the closed form was 
28 Å, the semi-opened form 34 Å and the opened form 43 Å[12].  When employing the 






between the α-carbon of K55 and K154 of the unbound C-SA PR was ~23 Å, ~ 30 Å 
and >35 Å for closed (at ~ 0-1 ns), semi-opened (at ~ 2-3 ns) and opened form (at ~ 3.5 
ns and ~ 7 ns, and ~ 8-9 ns), respectively (see Figure 30).  The values obtained in this 
study for C-SA PR were different from the ones proposed by Karthik et al. for subtype 
B, but both follow the same trend.  This metric gives more information about the extent 
of flap opening however it does not show the flap tips behaviour that results into flap-
curling.  
Inhibitor bound C-SA PR 
It was found that the PCU-based inhibitors and ritonavir complexes remained in the 
closed form, corresponding to approximately 23 Å or less.  Figure 30 A-E shows the 
K55 - K154 distance evolutions for the PCU-based compounds.  It was observed that 
the PCU-based compounds gave no significant difference in the distance evolution 
compared with the ritonavir complex.  In comparison to the previously discussed 
parameter (distance of I50 - I149) it was found that these results do not conclusively 
describe the extent of the flap opening.  Another parameter proposed by Seibold et 
al.[49] was the distance between the flap tips and the catalytic aspartic acid residue 







Figure 30. The evolution of the distance between the α-carbon atoms of residues K55 







It is clear that the PCU based inhibitors behave very similarly to ritonavir.  Since the 
latter is known to be considerable more active than the PCU derived inhibitors, it is 
apparent that analysis of flap movement during MD simulations is not sensitive enough 
to reflect qualitative comparisons between the strength of the interaction between the 
inhibitors and the enzyme.   
 
Natural substrate-bound 
For the subtype B complexes in Figure 31 A, it was found that both complexes showed 
similar distances for the first 5 ns.  However, the natural substrate tends to exhibit larger 
distances of about 16 Å for the second 5 ns.  In this case ritonavir forms a tighter 
complex during the last 5 ns in comparison to the natural substrate. 
Figure 31 B shows the K55 - K154 distance for the C-SA PR.  Distances of around 22 
Å were observed for the entire simulation, which means that the substrate is tightly held 
in the closed form.  This is in contrast to ritonavir, which showed fluctuations between 
20-25 Å.   
 
Figure 31. The evolution of the distance between the α-carbon atoms of residues K55 






Evaluating the distance between the flap tips (I50 Cα or I149 Cα) and 
catalytic aspartic acid (D25 Cβ or D124 Cβ) for the PR as suitable flap 
dynamics metric. 
Unbound C-SAPR 
Seibold et al. also reported that measuring the distance between I50 and I149 is not the 
best parameter to monitor the extent of flap opening as it can be affected by flap-curling 
and flap asymmetry; therefore, it was proposed that the distance between the flap tip 
residues (I50 Cα or I149 Cα) and Asp catalytic residues (Asp25 Cβ and Asp124 Cβ) 
should be measured[74].  
 Figure 32 and Figure 33 show the distances for both the free enzymes and the 
inhibitor/enzyme complexes.  It was found that the two flaps from each monomer 
behave differently.  In the range of 0-4 ns, flap A of monomer A (I50 Cα - Asp25 Cβ) 
fluctuated between 19 Å and 31 Å (see Figure 32) while for flap B of monomer B (I149 
Cα - Asp124 Cβ) the fluctuations increases from 10 Å to 28 Å with time (Figure 33) in 
the unbound C-SA PR.  These results show that flap A is far from the catalytic site 
while flap B is close to the catalytic site.  For both flaps the distance between the flap 
tips and catalytic aspartic acid was observed to decrease to 15 Å at ~4.5 ns and an 
increase to an average distance of 25 Å at 5 ns was observed.  This shows that the flap 
movements are asymmetric.  
 
Inhibitor bound C-SA PR 
In comparing the distance between the flap tips and the catalytic aspartic acid, it was 
found that flap A (monomer A) of the unbound C-SA HIV PR behaves differently to 
when it is complexed.  Interestingly, it was observed that the monomers, A and B, also, 
behave differently in the complexes. 
Figure 32 A-E show that these complexes exhibited similar interaction behaviour with 
monomer A, for the first 6 ns, since the distances between the catalytic site and flap tips 






flap is pulled more inward, towards the catalytic site by hydrogen bonding than the 
other flap which is further away from catalytic site.  In contrast, the measured distances 
for monomer B in the ritonavir/enzyme complex was relatively similar to the unbound 
PR (see Figure 33).  The PCU-based compound/enzyme complexes (see Figure 33 A-E) 
showed relatively similar fluctuation as the ritonavir complex.  However, in some cases, 
the PCU-based compound/enzyme complexes exhibit smaller distances which shows 
that flap B is pulled more toward the catalytic site.  In Figure 33 B, the PCU-diol 
peptoid complex shows smaller distances after 1.8 ns for the entire simulation when 
compared with the ritonavir complex.  This demonstrates that flap B of the PCU-diol 







Figure 32.The evolution of the distance between the catalytic site and flap tip, for the β-
carbon atom of residue D25 and the α-carbon atoms of residues Ile50 in monomer A in 







Figure 33. The evolution of the distance between the β-carbon atom of residue D124 







It is also apparent that with this metric parameter the analysis of flap movement during 
MD simulations is not sensitive enough to reflect qualitative comparisons between the 
strength of the interaction between the inhibitors and the enzyme.   
 
Natural substrate bound to PR results 
Figure 34 displays the distance between the catalytic aspartic residues and the flap tips, 
for subtype B PR (A) and C-SA PR (B).  The natural substrate/subtype B complex 
exhibited shorter distances than ritonavir complex (Figure 34 A).  The natural substrate 
is tightly held, thus, making the active site pocket smaller. 
Conversely, ritonavir complexed with C-SA PR exhibited shorter distances than the 
natural substrate complex (Figure 34 B).  This shows that the flap A of monomer A is 




Figure 34. The evolution of the distance between the catalytic site and flap tip for 
between the β-carbon atom of residue D25 and the α-carbon atoms of residues Ile50 in 






Figure 35 shows the evolution of the distance between the β-carbon atom of residue 
D124 and the α-carbon atoms of residues Ile149 in monomer B for subtype B PR (A) 
and C-SA PR (B). 
The natural substrate and ritonavir complexes with subtype B PR exhibited similar 
distances (Figure 35 A) for the first 5 ns but between 5-8 ns the natural substrate 
showed smaller distances than the ritonavir complex.  The last 2 ns for both complexes 
showed the same distances. 
In Figure 35 B, flap B of monomer B in the natural substrate complex showed much 
smaller distances (about 12 Å) than for the ritonavir complex which tend to exhibit 
same distances (about 20 Å) as the unbound C-SA PR.  In this case, when the natural 
substrate is complexed to C-SA HIV-1 PR the more tightly, the closed form is observed.  
It is possible that this is one of the reasons for the poor response when ritonavir is given 
to patients with the subtype C strain.  
 
 
Figure 35. The evolution of the distance between the β-carbon atom of residue D124 
and the α-carbon atoms of residues Ile149, in monomer B for subtype B PR (A) and C-








RMSD for the backbone α-carbons 
Figure 36 shows the RMSD of all backbone carbons.  This, therefore, gives a measure 
of the flexibility of the protein as a whole.  Similar to the plots generated by measuring 
the distance between the α-carbon residues of K55 and K154, the backbone RMSD 
plots showed the same trend for the complexes and for the unbound C-SA HIV PR.  
The unbound C-SA PR showed greater flexibility (greater than 2 Å) throughout the 
entire simulation while the complexes exhibited less flexibility with the average RMDS 














Figure 37 A shows the RMSD for the natural substrate and ritonavir complexed with 
subtype B PR.  Both complexes exhibit the same deviations in the first 4 ns; however, 
between 4 ns and 10 ns the natural substrate complex exhibited smaller deviations than 
the ritonavir complex. 
Figure 37 B shows the backbone RMSD plots for the unbound, substrate bound and 
ritonavir bound subtype C PR.  The natural substrate complex exhibited smaller 
deviations than the ritonavir complexed with C-SA HIV PR.   
 
Figure 37. Backbone RMSD for the complexes and unbound  subtype B PR (A) and C-
SA PR (B) (implicit water solvent, 300K). 
 
RMSF of the α-carbons of all residues 
Unbound C-SA PR 
The mobility of the flaps (residues 43-58 of flap A and 142-157 of flap B) in the 
unbound C-SA PR is greater than the ligand bound complex of all investigated ligands 
as shown by the RMSF of the α-carbon atoms (Figure 38 A-E).  In the unbound PR 
dimer, flap A was more flexible than flap B, where the atomic fluctuation of the α-






43-58 (flap A) and residues 142-157 (flap B), thus, indicating a closed conformation of 
most of the complexes.  
By comparison with all complexes, the PCU-diol peptide and PCU-diol peptoid (Figure 
38 A and Figure 38 B) showed more flap movement while PCU-ether peptide and PCU-
lactam peptide complexes were found to exhibit much lower flap fluctuation (Figure 38 
C and Figure 38 D).  This indicates that the flaps are held tightly by hydrogen bonding 
interactions to prevent flap fluctuations.  On the other hand, the lactam peptoid (Figure 
38 E) complex exhibited similar flap fluctuations as the unbound C-SA PR; this is 








Figure 38. RMSF of the  Cα atoms for the complexes and unbound C-SA HIV-1 PR 







Figure 39 shows the RMSF for the natural substrate bound to (A) subtype B PR and (B) 
C-SA PR.  There is a reduction of RMSF for flap A and B for both HIV PRs.  However 
the natural substrate bound to subtype B PR (Figure 39 A) seems to exhibit greater 
reduction in flap A (residues 43-58) than in flap B (residues 142-157).  In Figure 39 B 
the ritonavir complex and the natural substrate complex showed relatively similar 
reduction of the flap motion. 
 
Figure 39. RMSF of the Cα atoms for the complexes, unbound subtype B HIV-1 PR (A) 
and unbound C-SA HIV-1 PR (B) (implicit water solvent, 300K). 
 
Comparisons of unbound PR flap-curling with the curling of complexes 
Scott et al.[25] observed, flap-curling, which was suggested to trigger flaps opening.  
During flap-curling, the angle formed from the α-carbons of residues G48-G49-I50 of 
monomer A and G147-G148-I149 of monomer B were proposed to monitor the flap-
curling behaviour[49] (see Figure 40 A and B).  The curling-in of the flaps results in the 
reduction of the angle from around 145° to 90°-120°.  The lower angles represent the 
semi-open, curled or open form while angles above 120° represent the closed 
conformation.  This parameter does not clearly define the conformation of the flaps or 






to trigger flap opening however, in the complexes the curling event was due to the 
interaction between the flaps, the inhibitor and the P1 loop (residues Pro79/Pro178, 
Thr80/Thr179 and Pro81/Pro180 from the protease).  These interactions also contribute 
to the stability of the closed form and hence the entire complex.   
 
 
Figure 40. Flap-curling is defined by the angle formed from the three Cα of G48-G49-
I50 in monomer A (A) and G147-G148-I149 in monomer B (B) versus time (implicit 
water solvent, 300K). 
 
Comparisons between the inhibitors experimentally obtained IC50 with the 
observed MD results from the investigated matrices 
The PCU-based compounds have been biologically tested ant their IC50 were shown in 
Figure 21.  The PCU-lactam peptide showed the lowest IC50 of 78 nM while ritonavir 
exhibited[55] an IC50 of about 22-13 nM.  When looking at the MD results and the flap 
movement measurements for the investigated PCU compounds it is clear that a 
quantitative relationship between the reported activities and the observed flap 








To gain insight into the flap flexibility, MD simulations with implicit solvation were 
employed since shorter MD times explore the full conformational profile of the C-SA 
PR.  Comparisons were made between the unbound and bound proteases.  Comparisons 
between subtype B and C-SA PR showed that C-SAPR exhibits higher flexibility than 
subtype B; this is in agreement with the results by Naicker et al.[50].  Furthermore, it 
was found that the C-SA PR explored three forms during a 10 ns MD run (implicit 
water as solvent) i.e. a closed, semi-opened and opened form while the subtype B PR 
was dominated by the opened form.  With reference to the measured parameters it was 
found that all complexes attained a closed form most of the time.  This indicates that the 
presence of an inhibitor reduces the flap fluctuations, thus, preventing it from opening.  
The metric method for measuring the distance between the flap tips (Cα I50 – Cα I149) 
did not show entirely the extent of flap opening since it was affected by the curling of 
the flap tips which gave a false representation of flap opening while the flaps were in 
fact only curled.  On the other hand, the metric for measuring the distance between the 
Cα K55 – Cα K154 showed complete flap movement while the distance between the 
flap tip and catalytic site (I50 Cα- Asp25 Cβ) and (I149 Cα- Asp124 Cβ) showed the 
tightness of the inhibitor in the active site.  It was also found that measuring the dihedral 
angles [CAs of G48-G49-I50 (G147-G148-I149) monomer A (monomer B)] of the flap 
tips only shows which angles represent which conformations but not the extent of flap 
movement.  Therefore, the best method to measure the extent of flap opening is by 
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Virtual Screening of PCU-diol peptides as potential C-SA HIV-1 PR 
 
4.1 Abstract 
Virtual screening of a total of 640 cage-peptide based inhibitors was performed to gain insight into 
the structure-activity relationship of these potential inhibitors against C-SA HIV PR.  The overall 
results showed that compounds with the amino terminal (N→C connectivity) had improved binding 
energies when compared to the carboxyl terminal (C→N connectivity).  The most active agents 
were found to be the amino terminal compounds with a linker distance of n = 2 and 3.  There was 
no real trend in the chirality effect however more prominent energy differences were observed in 
some diastereomers with the carboxyl and amino terminal for n = 3 and n = 2, respectively.  
Compounds with bulky hydrophobic amino acids were found to be the most favoured when 
compared to less hydrophobic, polar, charged, basic and acidic residues in both carboxyl and amino 
terminal.   
 
4.2 Introduction 
The active site pocket of the HIV-1 PR is made up with several well-known subsites where the 
respective side chains of the substrates are positioned upon binding[1].  It has been reported in 
literature that a phenylalanine residue frequently occupies the S1 subsite and 40% of the Gag-pol 
polyprotein precursor gene sequences of the virus consist of phenylalanine[2, 3].  It is also known 
from literature that the S1/S1' subsites preferentially accommodates bulky hydrophobic residues 
(such as phenylalanine) while the S2/S2' and S3/S3' subsites prefer both hydrophilic and hydrophobic 
residues such as valine and alanine[4, 5]. 
There are currently eleven commercial HIV-1 PR inhibitors approved by the Food and Drug 
Administration (FDA) in the USA and a number of others are currently undergoing clinical 
trials[6]. 
Previous non-HIV related studies reported that the inclusion of a hydrocarbon cage skeleton into 
biologically active compounds advanced their function as a result of the ability of the drug to cross 






cage.  It also reduces the metabolic degradation of the drug thereby prolonging its pharmaceutical 
effect in the body[7-11]. 
We have reported the synthesis[5, 11-13], computational studies[3, 5, 9, 14, 15], NMR [10, 12, 13] 
and biological testing[3, 5] of a series of pentacycloundecane (PCU)-based peptides and peptoids as 
potential South African HIV-1 protease subtype (C-SA HIV PR) inhibitors.  The best inhibitory 
activities (IC50) observed from in vitro analysis for both cage lactam peptides (Figure 41, represent 
compound 1 with 78 nM) and peptoids in the 70 nM range.  It was concluded from these 
comprehensive studies, that the PCU skeleton occupies the S1/S1' subsites while the peptide side 
chains fit the S2/S2' and S3/S3' sites.   
Moreover, these studies confirmed that variation of the amino acids of the peptide side chain (or the 
corresponding peptoids) has a remarkable influence on the inhibitory activity of these compounds 
towards the C-SA HIV PR.  We have previously demonstrated that the chirality of the cage is 
important and as expected, leading to different observed HIV inhibition activities[5]. 
 
 
Figure 41. Structures of the previously synthesized and biologically tested PCU-lactam peptide[5]. 
 
Our previous studies concluded, that the docking results for these compounds give reasonable 
agreement with the experimentally observed inhibition activities (IC50)[16].  However, there are 
two potential reasons for not getting a correlation between the docked results and IC50: (a) the 
docking binding energies are not sophisticated enough and (b) as we have shown[17], experimental 
IC50 results tend to vary from one reported literature value to the next.   
It appeared to us that the symmetrical cage diol compounds[18] which have two peptide side chains 
(2a and 2b, Figure 42) should in theory be able to form more hydrogen bonds with the PR active 




























































2b (IC50 = 500 nM)
 
Figure 42. Structures of the previously synthesized and biologically tested PCU-diol peptides 
against C-SA HIV-1 PR[18]. 
 
In general, these cage diol peptides exhibited more than an order of magnitude lower activity 
against HIV PR than the best lactam peptide or peptoid.   
It was argued[18] that variation of the length of the linker[22-25] between the cage and the peptide 
combined with a variation of the amino acid chirality on either side, may enable us to design more 








Figure 43. Model structure for the PCU-diol peptides to be investigated.  The R groups are 
represented by the nineteen natural amino acids as well as 2-phenylglycine (Phg) with four different 
diastereomers for both cage1 and cage2 (20 x 4 x 2 = 160 compounds).  This was done for n = 0 – 3 
(160 x 4 = 640 compounds). 
 
It is important, to note that some of these compounds (such as cage2, n = 0, 1) would be difficult if 
not impossible, to synthesise.    
The aim of this study is to propose and test a suitable computational model to further optimize the 
potential of the PCU-diol compounds against C-SA HIV-1 PR, (see Figure 43, cage1 and cage2).  
In order to achieve that molecular docking will be used to determine the interactions (binding free 
energies) of the PCU systems with C-SA PR.  With respect to complexation to the PR we will 
attempt to answer the following questions:  
1. To determine whether C→N (R-cage1-R) or N→C (R-cage2-R) amino acid attachment to 
the cage gives optimum binding to the PR active site. 
2. The optimal linker distance (n = 0, 1, 2 or 3) of these amino acids to the cage skeleton.  
3. The most favourable amino acid(s) and its chirality to be attached to the cage-diol skeleton 
for the best complimentary interaction with HIV-PR (C-SA). 
To accomplish these objectives, we conducted an extensive virtual screening study to obtain a 
theoretical Structure-Activity Relationship (SAR) of a large number of these compounds.  It is 
important to note that the symmetric cage diol becomes chiral (10 of the 11 carbon atoms) when a 
chiral residue is attached to any (or both) of the two side chains[18].  Variation of the chirality of 
the amino acid side chains (attached to both sides) therefore, results in the formation of four 
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attached to both side of the cage because an additional (second) amino acid will protrude out of the 
enzyme and exhibit limited hydrogen bond contribution.   
Docking simulations for all natural amino acid and 2-phenylglycine with four different 
diastereomers at different separation distances (n) from the cage framework were performed for 
both cage1 and cage2 (Figure 43).  This involved 640 different molecules.   
4.3 Materials and methods 
4.3.1 Computational simulations 
The following sections present an outline about the preparation of the ligands and receptors for 
molecular modelling.  It also provides details of the software and the parameters that were 
employed.   
 
4.3.1.1 Preparation of PCU-derived peptide inhibitors 
PCU-diol peptide-based compounds were constructed and optimized with the molecular mechanics 
optimization force field implemented in Hyperchem 6.0 software[26] and the dihedral angles for all 
amide bonds were 180°.  The trans conformation of the amide bond requires 88 kJ/mol (21 
kcal/mol) for rotation about C-N bond to form the cis conformation[27].  Since this does not occur 
at room temperature, the trans amide bond was fixed during docking.  Nineteen natural amino acids 
as well as 2-phenylglycine (Phg) with four different diastereomers were studied for both cage1 and 
cage2 (20 x 4 x 2 = 160 compounds).  This was done for n = 0 – 3 (160 x 4 = 640 compounds).  The 
ionization states of the aliphatic amine and carboxylic acids groups of the PCU-based peptide 
inhibitors were reported to have no significant effects on the docking results when they are either in 
the neutral or ionized states[15].  These resulted in the screening of a total of 640 neutral 
compounds against C-SA HIV-1 protease.  The minimized structures were then subjected to 
docking studies. 
4.3.1.2 C-SA HIV-1 PR enzyme model system 
The model structure of the C-SA HIV-1 PR has been explained in detail in Section 3.3.1.2 
 
4.3.1.3 Docking of the inhibitors into the active site of the C-SA HIV-1 PR model 







4.4 Results and discussion 
Virtual screening 
In all the investigated amino acids with n = 0 of cage1 compounds (see Figure 44), the (S)-Trp-
cage1-Trp-(R) was observed to be the best with a figure of -9.29 kcal/mol followed by (R)-Pro-
cage1-Pro-(R), (S)-Phg-cage1-Phg-(R), (R)-Tyr-cage1-Try-(S) and (R)-Phe-cage1-Phe-(R) with -
8.45 kcal/mol, -8.39 kcal/mol, -8.37 kcal/mol and -7.86 kcal/mol, respectively.  When looking at 
the chirality effect for the most favoured amino acids with strong binding, it was found that there is 
no real trend in the binding energies.   
Thus, the attachment of bulky hydrophobic residues (Trp, Pro, Phg, Tyr and Phe) for some 
diastereomers directly to the PCU cage results in the most favourable binding energies with the PR 
in comparison to the less hydrophobic (Ala, Ile, Leu and Val), polar (Asn, Met, Cys, Ser, Gln and 
Thr), charged basic residues (Arg, His and Lys).  The poorest results were obtained with the acidic 
residues Asp and Glu.  The bulky hydrophobic residues are expected to occupy S2/S2ʹ′subsites since 
the cage skeleton occupies the S1/S1ʹ′subsites.   
 
 
Figure 44. A graph representing the virtual screening results of all 20 investigated amino acids for 
the carboxyl terminal, when n = 0 for R-cage1-R. 
 
The best result in Figure 45, when n = 1 for cage1, was observed for (S)-Trp-cage1-Trp-(R) with -

























































































Tyr-cage1-Tyr-(R), (R)-Phg-cage1-Phg-(S) and (S)-Ile-cage1-Ile-(S) however showed better binding 
with binding energies of -8.51 kcal/mol, -8.46 kcal/mol, -8.23 kcal/mol and -7.91 kcal/mol, 
respectively but with different trends to Figure 44.  Similarly, it appears that there is no obvious 
trend in the binding energies with relation to any particular chiral arrangement.   
 
The (S)-Trp-cage1-Trp-(R) inhibitor showed the binding energy of -9.29 kcal/mol in Figure 44 
while in Figure 45 it was -8.69 kcal/mol.  This indicates that increasing the linker from n = 0 to n = 
1 resulted in a decrease in the binding activity.  A decrease in the binding energies were also 
observed for the (R)-Pro-cage1-Pro-(R), (S)-Phg-cage1-Phg-(R) and (R)-Tyr-cage1-Tyr-(S) 
inhibitors.  The binding energies for these compounds in Figure 44 were -8.45 kcal/mol, -8.39 
kcal/mol and -8.37 kcal/mol while in Figure 45 they were -6.81 kcal/mol, -7.90 kcal/mol and -7.29 
kcal/mol, respectively.  In contrast the (R)-Phe-cage1-Phe-(R) inhibitor showed an increase in the 
binding energy from n = 0 to n = 1.  When n = 0 the binding energy was -7.86 kcal/mol and when n 
= 1 it was -8.30 kcal/mol. 
 
 
Figure 45. A graph representing the virtual screening results of all 20 investigated amino acids for 
the carboxyl terminal, when n = 1 for R-cage1-R. 
 
As the number of methylene spacers increases it is believed that the amino acids residues will 
occupy other subsites.  The best inhibitors for cage1 when n = 2, (see Figure 46) were (R)-Phe-

























































































cage1-Leu-(S) with binding energies of -8.87 kcal/mol, -8.81 kcal/mol, -8.61 kcal/mol, -8.46 
kcal/mol and -8.26 kcal/mol, respectively.  There was a significant increase in the binding ability 
for the (S)-Leu-cage1-Leu-(S).    
 
 
Figure 46. A graph representing the virtual screening results of all 20 investigated amino acids for 
the carboxyl terminal, when n = 2 for R-cage1-R. 
 
As the distance of the linker between the cage skeleton and the side chains increased further (n = 3), 
the (R)-Phe-cage1-Phe-(R) was the best inhibitor with -9.94 kcal/mol, (see Figure 47).  Other bulky 
compounds, such as (S)-Phg-cage1-Phg-(R), (S)-Pro-cage1-Pro-(R) and (R)-Trp-cage1-Trp-(S) gave 
the most promising complexing energies with -8.80 kcal/mol, -7.95 kcal/mol, -7.77 kcal/mol, 
respectively.  For these compounds once again, there was no real trend in the chirality effect.  
Interestingly, amongst the hydrophilic species there appears to be an increasing trend in favour of 
one or more particular diastereomer.  For example, (R)-Lys-cage1-Lys-(R) renders a uniquely lower 
energy of -7.41 kcal/mol compared to its other chiral equivalents at around 4 kcal/mol.   
The overall results for the cage1 compounds, with n = 0 – 3, showed that irrespective of the spacer 
length the bulky hydrophobic amino acids are the best compounds when compared to the less 
hydrophobic, polar, charged, acidic or basic examples.  The investigation of the chirality effect 
























































































compounds with Asp and Glu residues would be poor candidates for inhibitor synthesis as they 
consistently yielded poor results.  
 
 
Figure 47. A graph representing the virtual screening results of all 20 investigated amino acids for 
the carboxyl terminal, when n = 3 for R-cage1-R. 
 
Figure 48, shows the cage2 compounds when n = 0.  It was observed that the best inhibitor was (R)-
Phg-cage2-Phg-(R) with the binding energy of -11.92 kcal/mol.  The other promising compounds 
were (R)-Phe-cage2-Phe(S), (R)-Trp-cage2-Trp-(R), (R)-Tyr-cage2-Tyr-(R) and (R)-Thr-cage2-Thr-
(S) with the binding energies of -11.36 kcal/mol, -11.08 kcal/mol, -10,56 kcal/mol, -9.84 kcal/mol, 
respectively.  The overall energy results in this case for the more hydrophobic amino acids are 
closer in value to the compounds with bulky hydrophobic residues.  It is observed that the inhibitors 
with N→C connectivity (R-cage2-R), exhibit slightly improved binding energies compared to those 




























































































Figure 48. A graph representing the virtual screening results of all 20 investigated amino acids for 
the amino terminal, when n = 0 for R-cage2-R. 
 
When the linker was n = 1, (see Figure 49) in R-cage2-R, the best inhibitor was (S)-Phg-cage2-Phg-
(S) with -12.22 kcal/mol followed by (R)-Phe-cage2-Phe-(R), (R)-Trp-cage2-Trp-(R), (R)-Tyr-
cage2-Tyr-(R) with binding energies of -11.41 kcal/mol, -10.83 kcal/mol and -10.44 kcal/mol, 
respectively.  The result for (S)-Phg-cage2-Phg-(S) is the same as for n = 0, but in that case the 




























































































Figure 49. A graph representing the virtual screening results of all 20 investigated amino acids for 
the amino terminal, when n = 1 for R-cage2-R.  
 
For the n = 2 for cage2, the best binding energies observed were for (S)-Trp-cage2-Trp-(S), (R)-
Phg-cage2-Phg-(R), (S)-Val-cage2-Val-(R), (S)-Ile-cage2-Ile-(R) and (S)-Gln-cage2-Gln-(S) with 
binding energies of -12.44 kcal/mol, -12.32 kcal/mol, -11.78 kcal/mol, -11.67 kcal/mol and -10.60 
kcal/mol, respectively.  It is observed that across the graph all residues exhibit improved binding for 
the amino terminal (N→C connectivity) when n = 2 for cage2 compounds compared to n = 1 (see 
Figure 50).  Interestingly, a similar trend as was the case for cage1 n = 3 is observed in these 
results.  In particular there is an increasing trend in favour of one or more particular diastereomer 





























































































Figure 50. A graph representing the virtual screening results of all 20 investigated amino acids for 
the amino terminal, when n = 2 for R-cage2-R. 
 
When n = 3 (see Figure 51) it was observed that the best compounds were the (S)-Phg-cage2-Phg-
(R), (S)-Phe-cage2-Phe-(R), (R)-Tyr-cage2-Tyr-(R), (R)-His-cage2-His-(S) and (S)-Val-cage2-Val-
(R) with the binding energies of -12.05 kcal/mol, -11.85 kcal/mol, -10.19 kcal/mol, -9.94 kcal/mol 
and -9.74 kcal/mol, respectively.  The diastereomer binding energy trend observed for n = 2 for 





























































































Figure 51. A graph representing the virtual screening results of all 20 investigated amino acids for 
the amino terminal, when n = 3 for R-cage2-R. 
 
4.5 Conclusion 
In the overall results for the carboxyl terminal (C→N connectivity), it was revealed the bulky 
hydrophobic residues gives the best binding when n = 0 and n = 1, with slightly weaker binding 
when n = 2 and n = 3.  The inhibitors containing acid residues (aspartic acid and glutamic acid) 
consistently exhibited weak binding for n = 0, 1, 2 and 3.  Although there was no real trend in the 
chirality for the cage1 compounds when n = 3, some diastereomers gave more prominent energy 
differences. 
The inhibitors with the amino terminal (N→C connectivity) showed improved binding energies 
when compared with the carboxyl terminal.  The most favoured amino acids, once again, were the 
ones with bulky hydrophobic residues.  In this family of compounds, as the spacer length increased 
the amino acids with more polar residues generally, showed an increase in binding energies. Again, 
there was no conclusive trend in the chirality for the cage2 compounds but when n = 2, a number of 
diastereomers gave more prominent energy differences.  Interestingly, in the case of the single 
“arm” lactam compound 1, the most effective agent had a hydrophilic amino acid attached to the 


























































































As was stated earlier, the synthesis of compounds based on cage2 (n = 0,1) would be not be facile.  
Fortunately, the results of this study demonstrate that the most active compounds would in fact be 
based on cage2 where n = 2, 3.   
   
In this study, PCU-diol peptides with ≥ 12 rotatable bonds were investigated.  Thus, the docked 
binding energies are anticipated to be of a crude nature.  The study does, however, show promising 
results for both families of compounds.  It is clear that the cage2 compounds render a larger range 
of synthetic options as the structure-activity trend is broader.  To verify these results, subsequent 
MD binding free energies calculations need to be undertaken.  The final results will then have to be 
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In Chapter 3, molecular dynamics simulation in implicit solvation was performed for the subtype B 
PR, C-SA PR, PCU-based compounds bound to C-SA PR and ritonavir, natural substrate bound to 
both proteases (subtype B and C-SA PR).  Ritonavir and a natural substrate were used as references.   
A comparative study between unbound subtype B and C-SA PR showed that C-SA PR exhibits 
higher flap flexibility than subtype B PR.  From the MD trajectories, it was observed that the 
subtype B PR opens at 3.4 ns and remained open for the entire simulation while in C-SA PR three 
conformations were observed i.e., closed, semi-opened and opened forms.  The unbound C-SA PR 
was observed to open at 3.5 ns and then returned to the semi-opened form.  A semi-opened form of 
the protease was observed after the curling conformation (at 2.0 ns), which resulted in an opened 
conformation at 3.5 ns.  The flaps returned to the semi-opened conformation at 4.3 ns.  At 5.2 ns, a 
second opened form was observed and a fully-opened form at 8.6 ns was reached with a flap 
separation (the Ile149-Ile50 distance) of 28 Å.   
When evaluating the extent of flap opening for both complexes and unbound PRs, it was found that 
all complexes had reduced the normal movement of the PR (subtype B and C-SA PR).  When the 
metric parameter for measuring the distance between the flap tips (Cα Ile50 – Cα Ile149) was used, 
it was found that the Cα Ile50 – Cα Ile149 metric was affected by flap-curling and flap asymmetry.  
Measuring the distance between the Cα K55 – Cα K154 seemed to give more accurate results about 
the extent of flap opening since it was not affected by flap-curling.  In addition, it was found that 
measuring the distance between the flap tips and the catalytic aspartic residues (I50 Cα- Asp25 Cβ) 
and (I149 Cα- Asp124 Cβ) gives more information about how tightly the inhibitor is held in the 
pocket.  Also, measuring the dihedral angles [CAs of G48-G49-I50 in monomer A (G147-G148-
I149 in monomer B)] of the flap tips only shows which angles represent which conformations but 
not the extent of flap movement.   
When looking at RMSF plots, it was found that the Asp25 and Asp124 for both unbound PRs and 
complexes gave similar distances.  The PCU-ether peptide and PCU-lactam peptide showed 
reduced flap movement while the PCU-lactam peptoid showed no reduction in the flap motion.  The 
PCU-diol peptide and PCU-diol peptoid showed relatively similar reduction of the flap movement.  
From these observations, it was clear that the PCU based compounds do affect the flap movement 






The PCU-based compounds, have been previously biologically tested but when looking at the MD 
results and the flap movement measurements, it is clear that a quantitative relationship between the 
reported activities and the observed flap movements is not identifiable. 
In Chapter 4, virtual screening of 640 inhibitors (see Figure 52) was performed with AutoDock.   
 
Figure 52. Model structure for the PCU-diol peptides to be investigated. 
 
It was found that in all cases, n = 0, 1, 2 and 3, the N→C (R-cage2-R) compound, exhibited higher 
binding energies than C→N (R-cage1-R).  Compounds with bulky hydrophobic amino acids, were 
found to be the most favoured when compared to less hydrophobic, polar, charged, basic and acidic 
residues in both carboxyl and amino terminal.  For the C→N (R-cage1-R) connectivity, it was 
found that Glu and Asp residues gave weak binding energies while they showed improved binding 
in cage2.  There was no conclusive trend in the chirality investigation however, more prominent 
energy differences were observed in some diastereomers with the carboxyl and amino terminal for n 
= 3 and n = 2, respectively.  
 
Recommendations 
Recently, the C-SA HIV PR crystal structure was solved thus, in future a similar study can be 
performed using this structure.  In the current simulation studies, the inhibitors moved in the active 
site during the MD simulation which was due to the inhibitor not fitting tightly in the PR active site.  
It is really important to make sure that the inhibitor is tightly held in the active site during docking 
for better binding.  Since, the comparisons of the flap movement for both unbound enzyme and the 
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understand how the new inhibitors behave in the active site thus, saving time and money required 
for synthesis.   
Optimization of the parameters for the explicit solvation model is required since it was observed 
that the method used in this study required much longer simulation times.  This approach should 
give results which are more closely related to the mode of action thus, the role of water molecules 
during catalysis can be investigated.  
In future, prior to MD simulations the initial conformation of the inhibitors should resemble the 
conformations obtained in crystallographic studies.  This would be useful in order to compare our 
PCU-based compounds with the approved antiviral drugs.  To gain more insight into the structure-
activity relationship for the PCU-based compounds, binding energies from the MD simulation 
should be calculated.  The obtained binding energies will then be compared with the experimental 
IC50 and how they affect the protease movement.  This approach will help us in understanding how 
the inhibitor behaves in the protease active site thus, helping in the design of more potent inhibitors 










Appendix A:  Chapter 3 supporting information 
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Figure 53.  The chosen docked structure for PCU-diol peptide C-SA PR. 
 
 







Figure 55. The chosen docked structure for PCU-ether peptide C-SA PR. 
 
 
















Chapter 3 input files for MD simulations 
B.1 Input files for MD simulations in explicit solvation 
The following in put files were used in this thesis.  
 
Partial minimization input file 
&cntrl 
  imin   = 1, 
  maxcyc = 2500, 
  ncyc   = 750, 
  ntb    = 1, 
  ntr    = 1, 
  cut    = 12.0, 
 / 
Hold the Protein fixed 
500.0 












Full minimization input file 
&cntrl 
  imin   = 1, 
  maxcyc = 200, 
  ncyc   = 50, 
  ntb    = 1, 
  ntr    = 0, 
  cut    = 12.0, 
  Drms   = 0.0001, 
/ 
 
Heating stage 1-6 input file 
The temperature of the heating stage one to six were as follows (0-50)K, (50-100)K, (100-150)K, 
(150-200)K, (200-250)K, (250-300)K, respectively 
 
&cntrl 
  imin= 0, 
  irest=0, 
  NTX=1,  
  ntb= 1, 
  NTPR=500, 
  NTWX=500, 






  ntr=1, 
  Tempi=00.0,  
  Temp0=50.0, 
  NTT=3, 
  gamma_ln=1.0,  
  NTC=2, 
  NTF=2,  
  cut= 12.0, 
  nstlim=2500, 
  dt=0.002, 
/ 
Keep Protein and inhibitor fixed with weak restraints 
10.0 




Data input file 
&cntrl 
  imin= 0, 
  irest=1, 






  ntb=2, 
  ntp=1, 
  PRES0=1.0, 
  TAUP=2.0, 
  NTPR=500, 
  NTWX=500, 
  ntr=0, 
  Tempi=300.0,  
  Temp0=300.0, 
  NTT=3, 
  gamma_ln=1.0,  
  NTC=2, 
  NTF=2,  
  cut=12.0, 
  nstlim=250000, 
  dt=0.002 
 / 
Input files for MD simulation in implicit solvation 
The following in put files were used in this thesis.  
Partial minimization input file 
&cntrl 






  maxcyc = 5000, 
  ncyc   = 2500, 
  ntb    = 0, 
  ntr    = 1, 
  cut    = 999.0, 
  IGB = 2 
 / 
Hold the Protein fixed 
500.0 




Full minimization input file 
&cntrl 
  imin   = 1, 
  maxcyc = 5000, 
  ncyc   = 2500, 
  ntb    = 0, 
  ntr    = 0, 
  cut    = 999.0, 






  Drms   = 0.0001 
 / 
 
Heating stages 1-6 input file 
The temperature of the heating stage one to six were as follows (0-50)K, (50-100)K, (100-150)K, 
(150-200)K, (200-250)K, (250-300)K, respectively. 
 
&cntrl 
  imin= 0, 
  irest=0, 
  NTX=1,  
  ntb= 0, 
  igb = 2, 
  NTPR=500, 
  NTWX=500, 
  NTWR=500, 
  ntr=1, 
  Tempi=00.0,  
  Temp0=50.0, 
  NTT=3, 
  gamma_ln=1.0,  
  NTC=2, 






  cut= 999.0, 
  nstlim=2500, 
  dt=0.002 
 / 
Keep Protein and inhibitor fixed with weak restraints 
10.0 




Data input file 
&cntrl 
  imin= 0, 
  irest=1, 
  NTX=5,  
  ntb=0, 
  igb=2, 
  TAUP=2.0, 
  NTPR=500, 
  NTWX=500, 
  ntr=0, 






  Temp0=300.0, 
  NTT=3, 
  gamma_ln=1.0,  
  NTC=2, 
  NTF=2,  
  cut=999.0, 
  nstlim=2500000, 








B.2 Data analysis parameters 
 
The data analysis was done using ptraj found in Amber and the plots created by Origin software. 
Measuring the distance between Cα Ile50 and Cα Ile149 
trajin Data_10ns.mdcrd 
distance DIST @2342 @778 out ptraj_distance.out 
 
Measuring the distance between Cα Lys55 and CαLys154 
trajin Data_10ns.mdcrd 
distance DIST @2414 @850 out ptraj_K55.out 
 
Measuring the distance between Cα Ile50 and Cβ Asp25 
trajin Data_10ns.mdcrd 
distance DIST @778 @407 out ptraj_monomerA.out 
 
Measuring the distance between Cα Ile149 and Cβ Asp 124 
trajin Data_10ns.mdcrd 
distance DIST @2342 @1971 out ptraj_monomerB.out 
 
Calculating the Flap A Cα RMSD 
trajin Data_10ns.mdcrd 







Calculating the Flap B Cα RMSD 
trajin Data_10ns.mdcrd 
rms first out rmsd_CA_B01 :142-157@CA 
 
Calculating RMSD for the backbone 
trajin Data_10ns.mdcrd 
rms first out rmsd @CA,C,N 
 
Calculating the RMSF of the backbone 
trajin Data_10ns.mdcrd  
atomicfluct out RMSF :1-198 byres 
 
Measuring the angle formed from Cα of G48-G49-I50 in monomer A 
trajin Data_10ns.mdcrd 
angle angle_nameA_01 @764 @771 @778 out angleA_01.dat time 1.0 
 
Measuring the angle formed from Cα of G147-G148-G149 in Monomer B 
trajin Data_10ns.mdcrd 
angle angle_nameB_01 @2328 @2335 @2342 out angleB_01.dat time 1.0 
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